W0 2012 / 013821 A1 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||. ( 12 ) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY ( PCT ) . ( 19 ) W0rld Intellectual Pr0perty Organizati0n. Internati0na1 Bureau. . ( 43 ) Internati0nal Publicati0n Date 2 February 2012 ( 02.02.2012 ) . . "I. n ‘ - " - " L , , ‘ . - : . - . ( 10 ) Internati0nal Publicati0n Number. WO 2012 / 013821 A1. . ( 51 ) . ( 21 ) . ( 22 ) . ( 25 ) . ( 26 ) ( 30 ) . ( 71 ) . ( 72 ) ( 75 ) . ( 74 ) . Internati0nal Patent Classiﬁcati0n : C ] 2N ] 5 / ] 13 ( 2010.01 ) A61P 35 / 00 ( 2006.01 ) A61K 31 / 7088 ( 2006.01 ) . Internati0nal Applicati0n Number : PCT / EP2011 / 063233. Internati0nal Filing Date : 1 August 2011 ( 01.08.2011 ) . Filing Language : Eng1ish Publicati0n Language : Eng1ish Pri0rity Data : . 10128452 30 Ju1y 2010 ( 30.07.2010 ) GB Applicants €0r dd deSignaied SraieS excepi US ) : VIB. VZW [ BE / BE ] ; RijVisschestraat 120 , B - 9052 Gent ( BE ) . KATHOLIEKE UNIVERSITEIT LEUVEN , K. U. LEUVEN R&D [ BE / BE ] ; Minderbr0edersstraat 8a - bus 5105 , B - 3000 LeuVen ( BE ) . Invent0rs ; and. Invent0rs / Applicants 0W US 0nZy ) : MARINE , JeanChrist0phe [ BE / BE ] ; Rue d ' Erbis0eu1 21 , B - 7050 Erbis0euI ( BE ) . LAMBERTZ , Irina [ BG / BE ] ; J0hannes Hartmann1aan 7C , B - 9040 Gent ( BE ) . C0mm0n RepresentatiVe : VIB VZW ; RijVisschestraat 120 , B - 9052 Gent ( BE ) . ( 81 ) . ( 84 ) . Designated States ( unZesS 0rherwise indicated , f0r every kind 0f naii0na1 pmieciion availabZe ) : AE , AG , AL , AM , AO , AT , AU , AZ , BA , BB , BG , BH , BR , BW , BY , BZ , CA , CH , CL , CN , CO , CR , CU , CZ , DE , DK , DM , DO , DZ , EC , EE , EG , ES , FI , GB , GD , GE , GH , GM , GT , HN , HR , HU , ID , IL , IN , IS , JP , KE , KG , KM , KN , KP , KR , KZ , LA , LC , LK , LR , LS , LT , LU , LY , MA , MD , ME , MG , MK , MN , MW , MX , MY , MZ , NA , NG , NI , NO , NZ , OM , PE , PG , PH , PL , PT , RO , RS , RU , SC , SD , SE , SG , SK , SL , SM , ST , SV , SY , TH , TJ , TM , TN , TR , TT , TZ , UA , UG , US , UZ , VC , VN , ZA , ZM , ZW. Designated States ( unZeSS 0rherwise indicated , f0r every kind 0fregi0naZ pmreciion avaiZabZe ) : ARIPO ( BW , GH , GM , KE , LR , LS , MW , MZ , NA , SD , SL , SZ , TZ , UG , ZM , ZW ) , Eurasian ( AM , AZ , BY , KG , KZ , MD , RU , TJ , TM ) , Eur0pean ( AL , AT , BE , BG , CH , CY , CZ , DE , DK , EE , ES , FI , FR , GB , GR , HR , HU , IE , IS , IT , LT , LU , LV , MC , MK , MT , NL , NO , PL , PT , RO , RS , SE , SI , SK , SM , TR ) , OAPI ( BF , BJ , CF , CG , CI , CM , GA , GN , GQ , GW , ML , MR , NE , SN , TD , TG ) . Published : . wirh internaii0naI Search rep0ri ( Ari. 21 ( 3 ) ) mm Sequence lisiing part 0fdeScripii0n ( Ride 5.2 ( a ) ) . . ( 54 ) Title : INHIBITION OF DICER FUNCTION FOR TREATMENT OF CANCER. ( 57 ) Abstract : The present app1icati0n re1ates t0 the ﬁe1d 0f cancer , particu1ar1y cancers wherein p53 tum0ur suppressi0n functi0n is 10st 0r impaired. It is sh0Wn herein that Dicer is a synthetic 1etha1 partner 0f p53 , a110Wing the se1ectiVe targeting and ki11ing 0f. cancer ce11s. The effects 0f Dicer 0n surViVa1 0n cancer ce11s are mediated thr0ugh the miR17 - 92 cluster and inhibiti0n 0f members 0f this nn ' RNA cluster is an attractiVe treatment strategy in cancer. M0st particu13r1y , these ﬁndings are 0f imp0rtance in the ﬁe1d 0f retin0bIast0ma. 10. 15. 20. 25. 30. WO 2012 / 013821 PCT / EP2011 / 063233. |NH|B|T|0N 0F D|CER FUNCT|ON FOR TREATMENT OF CANCER. Fie|d of the invention. The present app|ication re|ates to the fie|d 0f cancer , particu|ar|y cancers wherein p53 tumour suppression function is |ost or impaired. |t is shown herein that Dicer is a synthetic |etha| partner of p53 , a||owing the se|ective targeting and ki||ing of cancer ce||s. The effects of Dicer on surviva| on cancer ce||s are , at |east part|y , mediated thr0ugh the miR17 - 92 c|uster and inhibiti0n 0f members 0f this miRNA c|uster is an attractive treatment strategy in cancer. Most particu|ar|y , these findings are of. importance in the fie|d of retinob|astoma. Background. A |arge body 0f evidence indicates that a|terations in the expression of miRNAs contribute t0 cancer patho|ogies ( 1 ) . This is at |east part|y the consequence of reduced stabi|ity and / 0r activity 0f D|CER , an RNAse ||| endonuc|ease p|aying a critica| ro|e in miRNA biogenesis ( 2 - 6 ) . Consistent|y , Dicer1 is a hap|oinsufficient tumour suppressor in mice ( 7 , 8 ) , supporting the hypothesis that a decrease in Dicer1 function |eads to a g|oba| downregu|ation of miRs and promotes tumorigenesis. Surprising|y , however , homozyg0us de|eti0ns or |0ss - of - functi0n mutations in DICER1 d0 not 0ccur in human tumours and homozygous |oss of Dicer1 appears to be se|ected against in a K - Ras - induced mouse mode| of |ung. cancer ( 7 ) and Myc - induced mouse mode| of B - ce|| |ymphoma ( 9 ) . A vast majority of human cancers are a|so characterized by the |oss of p53 tumour suppression function ( 29 ) . Therefore , identification of synthetic |etha| interactors of p53 shou|d |ead to c0nceptua||y simp|e and attractive approaches t0 se|ective targeting 0f cancer ce||s. Synthetic |etha|ity has been proposed as an interesting concept in the context of anticancer therapy ( 30 ) . Two genes are synthetic |etha| if mutation of either a|one is compatib|e with viabi|ity but mutation of both |eads to death. ( "Synthetic" is thus used in the sense 0f synthesis , 0r coming together. ) So , targeting a gene that is synthetic |etha| to a cancer - re|evant mutation , |ike for instance in p53 , shou|d ki|| on|y cancer ce||s and spare norma| ce||s. Synthetic |etha|ity therefore provides a conceptua| framework for the deve|opment of cancer - specific cytotoxic agents. A|though it has been shown to work for ce||s that have |ost BRCA1 or BRCA2 ( 31 , 32 ) , no genetic / in vivo evidence for a synthetic |etha| interaction with p53 tumour suppressor has been described to date. Of note , a|so retinob|astoma ( Rb ) mutations are found in a majority of human cancers ( 33 , 34 ) . The Rb. gene was initia||y identified as a genetic |ocus associated with the deve|0pment of an inherited eye. 1. 10. 15. 20. 25. 30. WO 2012 / 013821 PCT / EP2011 / 063233. tumour. The rea|ization that it was a |oss of function of Rb that was associated with disease estab|ished the tumour suppressor paradigm. Mutations in Rb have a|so been semina| for the "two - hit hypothesis” 0f cancer , which states that cancer is the resu|t of accumu|ated mutations t0 a ce|| ' s DNA. Apart from its ro|e in eye tumours , |oss of Rb has for instance been demonstrated to increase the risk of osteosarcoma deve|opment in chi|dren and teenagers. |n adu|ts , human papi||omavirus ( HPV ) is thought to initiate cervica| carcinoma and squamous ce|| carcinoma of the head and neck in part by inactivating Rb through expression of the E7 oncoprotein , and simi|ar mechanisms are possib|y inv0|ved in virus - induced |iver cancers. Rb is inactivated in more than 90% of human sma|| - ce|| |ung carcinomas ( SCLC ) , and mouse genetic studies have confirmed that Rb is crucia| in preventing the initiati0n of this |ung cancer subtype. For an overview , see ref. 34 , particu|ar|y Tab|e 1 0f this reference , incorp0rated herewith. The disease retinob|astoma , affecting approximate|y 1 in 15 , 000 |ive births , is a rapid|y deve|oping cancer which deve|ops in the ce||s of retina , the |ight detecting tissue of the eye. Both genetic and sporadic forms of retinob|ast0ma exist , and |oss of Rb has been imp|icated in both. More0ver , it has recent|y been shown that , contrary to ear|ier suggestions , both the Rb and p53 pathways are. inactivated — a|though n0t necessari|y mutated - in retinob|astoma ( 13 ) . |t wou|d be advantageous to identify a synthetic |etha| partner for p53 , which w0u|d provide a new therapeutic target in cancer. |t wou|d be particu|ar|y advantageous if this a||ows the se|ective targeting of cancer ce||s in which more than one tumor suppressor pathway is compromised , such as for instance. retinob|astoma. Summary. The data presented herein sh0w that Dicer1 is required f0r tumour formati0n. |t is demonstrated that targeted homozygous |oss of Dicer1 comp|ete|y prevents the formation of retinob|astoma in mice in which the Rb and p53 tumour suppressor pathways are inactivated. Unexpected|y , this shows that Dicer1 deficiency se|ective|y ki||s Rb - deficient retina| ce||s in which p53 is inactivated whi|e sparing ce||s that retain functiona| p53. miRNA profi|ing of mouse and human primary retinob|astomas showed dramatic 0verexpression 0f the pr0 - onc0genic miR17 - 92 c|uster in a|| samp|es ana|yzed. Highreso|ution array - CGH indicates that in ~20% of human Retinob|astoma patients overexpression of miR17 - 92 resu|ts from copy number a|terations. Crucia||y , functiona| inactivation of the miRNAs enc0ded by the miR17 - 92 c|uster is sufficient t0 induce ap0ptotic death of human retin0b|astoma ce||s. Our data identify Dicer as the first synthetic |etha| partner of p53 and designate members of the miR - . 17 - 92 c|uster as a high|y se|ective therapeutic target for the treatment of retinob|astoma. 2. 10. 15. 20. 25. 30. WO 2012 / 013821 PCT / EP2011 / 063233. According|y , it is an object of the invention to provide methods of inducing ce|| death in a ce|| where p53 function is compromised , comprising inhibiting the function of Dicer. According to particu|ar embodiments , ce|| death is due to synthetic |etha|ity. According to particu|ar embodiments , in addition to the compromised function of p53 , the ce|| is further characterized by activation of an 0nc0gene or inhibition 0f a tumor suppressor gene ( such as e. g. Rb ) . According to specific embodiments , the ce|| wherein p53 function is compromised is a tumour ce||. Most particu|ar|y , the tum0ur is a retinob|astoma ( and the tum0ur ce|| thus is a retin0b|astoma ce|| ) . As wi|| be described herein , inhibiting the function 0f Dicer can be done in different ways. |t is particu|ar|y envisaged that the function of Dicer1 is inhibited by inhibiting one or more of the miRNAs that are upregu|ated in the ce|| where p53 function is impaired. These miRNAs are |isted in the app|ication ( e. g. in the tab|es pr0vided herein ) . According to particu|ar embodiments , the one or m0re miRNAs that are inhibited ( i. e. that are upregu|ated in the ce|| wherein p53 function is impaired ) are se|ected from the miR 17 - 92 c|uster or a para|og thereof ( such as the mir - 106a - 363 and mir - 106b - 25 c|uster ) . According t0 further particu|ar emb0diments , the one or m0re miRNA is se|ected from the miR 17 - 92 c|uster , most particu|ar|y se|ected from miR - 17 , miR - 18a , miR - 19a , miR - 19b , miR - 20a and miR - 92. As wi|| be described herein , inhibition of miRNAs can be done in severa| ways. According to particu|ar. embodiments , inhibiti0n 0f the miRNAs is with an LNA 0r an antagomir. Acc0rding t0 a|ternative embodiments , inhibiting the function of Dicer is done by inhibition 0f Dicer. itse|f , i. e. by inhibiting the Dicer1 gene , the Dicer1 mRNA or the Dicer protein. P53 function in the ce|| wherein p53 function is impaired can be impaired in different ways. According to particu|ar embodiments , p53 functi0n is impaired by functi0na| dysregu|ation but n0t mutation. According to a|ternative embodiments , p53 function is impaired by at |east one mutation. According to a further aspect , an inhibitor of Dicer function is provided for use in treatment of cancer. |n particu|ar embodiments , the cancer is retinob|astoma. According t0 specific embodiments , the inhibit0r 0f Dicer function is an inhibitor 0f one or m0re 0f the miRNAs that are upregu|ated in the cancer ce||s. More particu|ar|y , the miRNA is se|ected from the miR. 17 - 92 c|uster or a para|0g thereof ( such as the mir - 106a - 363 and mir - 106b—25 c|uster ) . According to. 3. 10. 15. 20. 25. 30. WO 2012 / 013821 PCT / EP2011 / 063233. further particu|ar embodiments , the one or more miRNA is se|ected from the miR 17 - 92 c|uster , most particu|ar|y se|ected from miR - 17 , miR - 18a , miR - 19a , miR - 19b , miR - 20a and miR - 92. According to a|ternative emb0diments , the inhibitor is an inhibit0r 0f the Dicer1 gene , the Dicer1. mRNA or the Dicer protein. Brief description of the Figures. Figure 1. Dicer1 is required for Retinob|astoma formation. ( A ) Kap|an - Meier curve showing the time to first 0bservation of externa||y visib|e retin0b|astoma. This time was marked|y decreased in Chx10Cre , ' Rb°X / f°X , ' p107 / ' ; p53f°X / °X ( TKO , b|ue |ine at bottom of graph ) mice re|ative to Chx10Cre ; Rb°X / "°X ; p107 / ' ( DKO , b|ack |ine in midd|e 0f graph ) |ittermates. Chx10Cre ; Rb"°X / "°X ; p107 / ] p53°X / "°X ; DicmX / f” ( QKO , red |ine at top of graph ) mice did not deve|op tumours ( |og rank test , P<0 , 0001 ) . ( B ) |nvasive tumours that fi|| the vitreous and the anterior chamber are found in TKO mice as ear|y as P60. Hematoxy|in and eosin stain with the three retina| nuc|ear |ayers ( GL : gang|i0n |ayer ; |NL : inner nuc|ear |ayer ; ONL : outer nuc|ear |ayer ) indicated. ( C ) K|67 and Chx10 , Syntaxin , and Ca|bindin immunostaining of DKO and QKO retinae at P14 and P45. B|ack Sca|e bars are = 40um and. the red sca|e bar in pane| B is = 400um. Figure 2. Chx10 / Rb / p107 - mutant ce||s are |ost upon concomitant inactivation of Dicer1 and p53. ( A ) Chx10 and GFP immun0staining 0f Chx10Cre ; Rb°X / °X ; p107 / ' ; Dicer°X / °X ; p53 + / + versus Chx10Cre , ' Rb°X / f°X , ' p107 / ' ; Dicer"X / "X ; p53f°X / "°X retinae at P48. GFP - positive ce||s are on|y detected in p53 wi|d - type mice. ( B ) AP - stained transverse retina| secti0ns from Chx10Cre ; Rb°X / °X ; p107 / ' ; Dicer°X / 0X ; p53 + / + and Chx10Cre ; Rb"°X / r°" ; p107 / ' ; Dicer°X / "°X ; p53r°X / °X adu|t mice ( P82 ) . Regions of AP reporter activity are on|y detected in p53 wi|d - type mice. ( A ) and ( B ) Sca|es bars =40um. ( C ) Schematic representation of the Dicer1 and p53 wi|d - type , f|oxed and Cre - excised a||e|es ( Top pane|s ) . DNA was prepared from P21 retinae of at |east 5 mice with the indicated genotypes and examined by PCR using. the primers depicted in the t0p pane|s. Representative PCRs are shown in the |ower pane|s. Figure 3. The miRNA - 17 - 92 c|uster is overexpressed in retinob|astoma and required for surviva| of estab|ished retinob|astoma ce|| |ines. ( A ) Heatmap of the miRNA - 17 - 92 and para|ogue c|usters in norma| mouse retina ( Chx10Cre—negative mice , |ight green ) , norma| human retina ( dark green ) , 4 mouse TKO tumours ( |ight b|ue ) and 3O different primary human retinob|astoma ( dark b|ue ) . ( B ) Expression ana|ysis by RT - qPCR of miR - 17 in norma| human retina and the estab|ished retinob|astoma ce|| |ines WER| - Rb1 and Y79. Data represents the mean of three independent experiments iSD. ( C ) . Transfection of miR17 - 92 specific inhibitors affect the surviva| of the retinob|astoma ce|| |ine WER| - RB1. 4. 10. 15. 20. 25. 30. WO 2012 / 013821 PCT / EP2011 / 063233. as assessed by MTT assay. The Y axis represents the re|ative percentage of viab|e ce||s fo||owing transfection of the miRNA - inhibitors. The data are norma|ized to the percentage of viab|e ce||s fo||owing transfecti0n of a scramb|e contro| o|ig0nuc|eotide. Data represents the mean 0f three independent experiments iSD. ( D ) Loss of Dicer1 protects against the formation of aggressive and invasive retinob|ast0ma by se|ective ki||ing of the Rb - deficient ce||s in which the p53 pathway is. inactivated. Figure 4. Dicer |oss does not affect retinogenesis. Chx10 and GFP immunostaining indicate the. ioX / ioX. presence of Dicer1 - deficient ce||s in adu|t retina of Chx10Cre ; Dicer mice. ( A ) construct used for GFP immunostaining. ( B ) Retina| |amination is norma| in these mice. ONL , outer nuc|ear |ayer ; RPE , . retina| pigment epithe|ium ; |NL , inner nuc|ear |ayer ; GL , gang|i0n |ayer. Sca|e bars = 40um. Detai|ed description Definitions The present invention wi|| be described with respect to particu|ar embodiments and with reference to. certain drawings but the invention is not |imited theret0 but on|y by the c|aims. Any reference signs in the c|aims sha|| not be construed as |imiting the scope. The drawings described are on|y schematic and are non - |imiting. |n the drawings , the size of some of the e|ements may be exaggerated and not drawn 0n sca|e for i||ustrative purposes. Where the term "comprising" is used in the present description and c|aims , it does not exc|ude other e|ements or steps. Where an indefinite or definite artic|e is used when referring to a singu|ar noun e. g. "a" or "an" , "the" , this inc|udes a p|ura| of that noun un|ess something. e|se is specifica||y stated. Furthermore , the terms first , second , third and the |ike in the descripti0n and in the c|aims , are used f0r distinguishing between simi|ar e|ements and not necessari|y for describing a sequentia| or chrono|ogica| order. |t is to be understood that the terms so used are interchangeab|e under appropriate circumstances and that the embodiments of the invention described herein are capab|e 0f. operation in other sequences than described or i||ustrated herein. The fo||0wing terms or definitions are provided so|e|y to aid in the understanding of the invention. Un|ess specifica||y defined herein , a|| terms used herein have the same meaning as they wou|d to one ski||ed in the art of the present invention. Practitioners are particu|ar|y directed to Sambrook et a|. , Mo|ecu|ar C|oning : A Laboratory Manua| , 2lnd ed. , Co|d Spring Harbor Press , P|ainsview , New York. ( 1989 ) ; and Ausube| et a|. , Current Protoco|s in Mo|ecu|ar Bio|ogy ( Supp|ement 47 ) , John Wi|ey & Sons , . 10. 15. 20. 25. 30. WO 2012 / 013821 PCT / EP2011 / 063233. New York ( 1999 ) , for definitions and terms of the art. The definitions provided herein shou|d not be. construed to have a scope |ess than understood by a person of ordinary ski|| in the art. As used herein , the term ”inducing ce|| death” refers to a process that resu|ts in the ki||ing of ce||s. Most particu|ar|y , as defined herein , the ce|| death is se|ective , i. e. ce|| death is induced in ce||s in which p53 function is compromised ( thus , those ce||s die ) and not induced in ce||s wherein p53 function is norma| ( those ce||s stay a|ive ) . According to particu|ar emb0diments , the term ”ce|| death” refers to. apoptotic ce|| death. The term ”p53 function” as used herein , refers to the tumor suppressor functi0n exerted by the p53 pr0tein enc0ded by the TP53 gene ( Gene |D : 7157 in humans ) . The tumor suppressor function of p53 invo|ves one or more of the fo||owing : activating DNA repair proteins when DNA has sustained damage ; inducing growth arrest by h0|ding the ce|| cyc|e at the Gl / S regu|ation point on DNA damage recognition ( if DNA repair proteins fix the damage , the ce|| wi|| typica||y be a||owed to continue the ce|| cyc|e ) ; and / or initiating apopt0sis if DNA damage pr0ves to be irreparab|e. ”Compromised function” or ”impaired function” as used throughout the app|ication , particu|ar|y in the context of p53 , refers to a reduced or absent functiona|ity of this tumor suppressor function. The function can be compr0mised because one or both copies of the TP53 gene are mutated 0r absent in the ce||s ( i. e. at the DNA |eve| ) , and / or because the gene is not correct|y transcribed or trans|ated ( i. e. at the RNA or protein |eve| , respective|y ) , and / 0r because no or mutant ( non - functiona| ) p53 pr0tein is expressed in the ce|| , and / or because |ower |eve|s of functiona| p53 protein are expressed in the ce||s. ”Lower |eve|s” as used herein means |ower |eve|s than those observed in a suitab|e popu|ation of contro| ce||s , particu|ar|y 25% |ower , 50% |ower or 75% or more |ower. For instance , 50% |ower expressi0n 0f functiona| p53 pr0tein may arise fr0m the |0ss of one functiona| p53 a||e|e. H0wever , a decrease in functiona| p53 |eve|s may a|so be the consequence of inactivation of components of the. p53 pathway or overexpression 0f other components , such as the p53 binding protein MDMX ( 13 ) . ”Dicer” as used herein refers to the protein product of the D|CER1 gene ( Gene |D : 23405 in humans ) . This gene enc0des a pr0tein possessing an RNA he|icase motif containing a DEXH box in its amino terminus and an RNA motif in the carboxy terminus. The encoded protein functions as a ribonuc|ease ( ribonuc|ease type ||| ) and is required by the RNA interference and sma|| tempora| RNA ( stRNA ) pathways to produce the active sma|| RNA component that represses gene expression. |n humans , two transcript variants encoding the same protein have been identified for this gene. The ”function of. Dicer” as used herein is the pr0cessing 0f microRNAs or miRNAs ( 35 , 36 ) , and ”inhibiting the function 0f 6. 10. 15. 20. 25. 30. WO 2012 / 013821 PCT / EP2011 / 063233. Dicer” consequent|y means inhibiting the function of correct|y processed miRNAs , be it by inhibiting their processing ( e. g. by direct|y interfering with Dicer ) or by inhibiting the miRNAs themse|ves ( e. g. via LNAs 0r antagomirs ) . According t0 particu|ar embodiments , ”inhibiting the function of Dicer in a ce|| where p53 function is compromised” means inhibiting the miRNAs that are upregu|ated in ce||s where p53 function is compromised , wherein upregu|ati0n shou|d be compared t0 suitab|e contro| ce||s wherein p53 function is not compromised. |n particu|ar embodiments , upregu|ation of miRNAs may a|so mean that they are expressed in ce||s wherein p53 function is compromised , whereas they are not expressed in contro| ce||s. According to very particu|ar embodiments , ”inhibiting the function of Dicer”. means ”inhibiting at |east one miRNA from the miR 17 - 92 c|uster”. According to the definitions herein , two genes are said to be in a ”synthetic |etha|” re|ationship or ”synthetic |etha| partners” or interactors if a mutation in , or downregu|ation or knockout of , either gene a|one is not |etha| but mutati0ns / downregu|ation / knockout in or 0f both cause the death of the ce||. Note that , according to this definition , genes can be synthetica||y |etha| if e. g. a mutation in one gene is combined with e. g. downregu|ation of the other gene. |n cancer research , a synthetic |ethapartner is a gene that , when mutated or 0therwise inhibited , ki||s ce||s that harbor a specific cancer - re|ated a|teration , such as a mutated tumor - suppressor gene or an activated oncogene , but spares otherwise identica| ce||s |acking the cancer - re|ated a|teration ( 30 ) . According to very particu|ar embodiments , the synthetic |etha| partner is synthetica||y |etha| with mutations in , or functionadysregu|ation of , p53. According to even more specific embodiments , the synthetic |etha| partner of p53 is Dicer or an effect0r of Dicer functi0n , such as a specific miRNA , particu|ar|y one 0f the miR 17 - 92. c|uster. An ”oncogene” as defined herein is a gene that has the potentia| to cause cancer. |n tumor ce||s , they are often mutated or expressed at high |eve|s. Typica||y , an oncogene is the resu|t of changes ( i. e. mutati0ns , overexpression ) of a norma| gene , termed proto - onc0gene. Proto - oncogenes typica||y code for pr0teins that he|p to regu|ate ce|| gr0wth and differentiation. The pr0t0 - 0nc0gene can become an oncogene by a re|ative|y sma|| modification of its origina| function , such as a mutation ( e. g. |eading to increase in protein or enzyme activity or |oss in regu|ati0n ) , increase in protein c0ncentration ( e. g. by protein overexpression , increase in mRNA stabi|ity or gene dup|ication ) , or chromosoma| trans|ocation ( |eading to e. g. aberrant expression or constitutive|y active fusion genes encoding hybrid proteins ) . C0nversi0n 0f pr0to - onc0genes in onc0genes can be quantitative or qua|itative. Non - |imiting examp|es of oncogenes ( or proto - oncogenes that can become oncogenes upon activation ) are |isted further in. the detai|ed description. 10. 15. 20. 25. 30. WO 2012 / 013821 PCT / EP2011 / 063233. A ”tumor suppressor gene” , or ”anti - oncogene” , as herein defined is a gene that protects a ce|| from 0ne step on the path to cancer. When this gene is mutated t0 cause a |oss or reduction in its function , the ce|| can progress to cancer , usua||y in combination with other genetic changes. Tumor - suppressor genes , 0r more precise|y , the pr0teins for which they code , either have a dampening or repressive effect on the regu|ation of the ce|| cyc|e or promote apoptosis , and sometimes do both. We|| - known examp|es of tumor suppressors are the p53 and retinob|astoma ( pr ) proteins. The ce|| cyc|e may be c0up|ed to DNA damage by tumor suppressors ( i. e. , as |ong as there is damaged DNA in the ce|| , it shou|d not divide. |f the damage can be repaired , the ce|| cyc|e can continue ) . |ndeed , increased mutation rate fr0m decreased DNA repair |eads to increased inactivation of other tumor suppressors and activation of oncogenes ( Markowitz , J C|in Onco|. 2000 ; 18 ( 21 Supp| ) : 75S - 80S ) . According|y , in particu|ar embodiments , DNA repair proteins are inc|uded in the definition of tumor suppressors. Non - |imiting examp|es of such DNA repair proteins whose mutation |eads to increased cancer risk inc|ude. HNPCC , MEN1 and BRCA. The disease ”retinob|astoma” as used herein refers to an embryonic ma|ignant neop|asm of retina|. origin ( OM|M + 180200 ) . The ”miR 17 - 92 c|uster” as used herein is a po|ycistronic c|uster consisting of different miRNAs that are processed from a common precursor transcript. The precursor transcript derived from the mir - 17 - 92 gene contains six tandem stem - |oop hairpin structures that u|timate|y yie|d six mature miRNAs : miR - 17 , miR - 18a , miR - 19a , miR - 20a , miR - 19b - 1 , and miR - 92 - 1 ( 18 , 37 , 38 ) . The six miRNAs encoded by mir - 17 - 92 can be categorized into three separate miRNA fami|ies according to their seed sequences : the miR - 17 fami|y ( inc|uding miR - 17 , miR - 20 , and miR - 18 ) , the miR - 19 fami|y ( miR - 19a and miR - 19b ) , and the miR - 92 fami|y ( 18 ) . |t is worth noting that miR - 18 exhibits a significant sequence homo|ogy with miR - 17 and. miR - 20 , despite 0ne nuc|eotide difference within the seed regions. Ancient gene dup|icati0ns have given rise to two mir - 17 - 92 c|uster para|ogs in mamma|s : mir - 106a - 363 and mir - 106b - 25 , each of which on|y contains homo|og0us miRNAs to a subset of mir - 17 - 92 components ( 18 , 37 , 38 ) , a|so referred t0 as para|ogs or para|og c|usters herein. The sequences of the miRNAs ( inc|uding seed regions ) and organization of the different c|usters can a|so be found in these references. microRNAs ( miRNAs ) are short ( typica||y 20 - 24 nt ) non - c0ding RNAs that are inv0|ved in p0sttranscriptiona| regu|ation of gene expression in mu|tice||u|ar organisms by affecting both the stabi|ity. and trans|ation 0f mRNAs. miRNAs are transcribed by RNA po|ymerase II as part of capped and. 8. 10. 15. 20. 25. 30. WO 2012 / 013821 PCT / EP2011 / 063233. po|yadeny|ated primary transcripts ( pri - miRNAs ) that can be either protein - coding or non - coding. The primary transcript is c|eaved by the Drosha ribonuc|ease ||| enzyme to produce an approximate|y 70 - nt stem - |oop precursor miRNA ( pre - miRNA ) , which is further c|eaved by the cyt0p|asmic Dicer ribonuc|ease to generate the mature miRNA and antisense miRNA star ( miRNA * ) products. The mature miRNA is incorporated into a RNA - induced si|encing comp|ex ( R|SC ) , which recognizes target mRNAs through imperfect base pairing with the miRNA and most common|y resu|ts in trans|ationa| inhibition. or destabi|ization of the target mRNA. According to a first aspect , methods are provided for inducing ce|| death in a ce|| where p53 function is compromised. These methods inv0|ve the inhibition of the function of Dicer. Acc0rding|y , it can be said that an inhibitor of Dicer function is provided for use in inducing ce|| death in a ce|| where p53 function is compromised. According t0 specific embodiments , the ce|| death that is induced is apoptotic ce|| death. According t0 particu|ar embodiments , inhibiting the function of Dicer in a ce|| where p53 function is compromised wi|| resu|t in synthetic |etha|ity. |. e. , inhibiting Dicer function in ce||s wherein p53 function is not compr0mised wi|| not ki|| the ce||s , but on|y when both p53 and Dicer function are compromised , the ce||s wi|| die. As p53 function is most typica||y compromised in tumor ce||s , it is particu|ar|y envisaged that the method can be used to ki|| tumor ce||s. ( |n other words , inhibitors of Dicer function are provided for use in treatment of cancer ) . Moreover , the ki||ing is se|ective , as ce||. death wi|| not be induced in ce||s where p53 function is norma|. |n cancer , it is often seen that the function of more than one tumor suppressor is compromised. Thus , ce|| death may a|so be induced in ce||s wherein , in addition to impaired p53 function , Rb function is compromised , and / or p107 function is compromised. However , the methods provided herein require defective p53 function for ce|| death to be induced , as inhibiting Dicer function in a ce|| with compr0mised Rb function but wherein p53 functi0ns norma||y wi|| not resu|t in ce|| death. |n other words , impaired Dicer function is synthetica||y |etha| with c0mpromised p53 function , but not with other tumor suppressors. Nonethe|ess , as cancer ce||s typica||y undergo many genetic changes , according to particu|ar embodiments , it is envisaged that the ce|| ( s ) to be ki||ed are characterized by impaired function of another tumor suppressor gene ( in addition to compromised function of p53 ) , and / or activation of one 0r more ( prot0 - ) oncogenes. The c0mpromised function 0r inhibition 0f the tumor suppressor gene may be through mutation of that gene ( e. g. in the case of BRCA ) , or as a resu|t of |ower expression / stabi|ity. of the gene product , 0r through genetic de|etion. The activation of one or more 0ncogenes ( or. 9. 10. 15. 20. 25. 30. WO 2012 / 013821 PCT / EP2011 / 063233. conversion of proto - oncogenes in oncogenes ) may occur through mutation , gene amp|ification / overexpression , or chromosoma| rearrangements. |n addition t0 TP53 , tumor suppressors that may a|so be impaired in the ce||s to be ki||ed inc|ude , but are not |imited to , Rb , APC , CD95 , ST5 , YPEL3 , ST7 , and ST14. As mentioned above , tumor suppressors may a|so inc|ude DNA repair proteins such as HNPCC , MEN1 and BRCA genes. A non - |imiting |ist of ( proto - ) oncogenes that may be activated or overexpressed in the ce||s to be ki||ed inc|udes : regu|atory GTPases such as RAS ; cytop|asmic Serine / threonine kinases or regu|atory subunits thereof , such as Raf kinases ( e. g. B - Raf , C - Raf ) , AKT1 , cyc|in - dependent kinases ( typica||y activated through overexpression ) ; cytop|asmic tyrosine kinases such as the Src - fami|y , Syk - ZAP - 70 fami|y , and BTK fami|y of tyrosine kinases , or fusion genes |ike Nup - Ab| , Bcr - Ab| ; recept0r tyrosine kinases such as EGFR , PDGFR , VEGFR , Her2 - Neu , Trk receptors or their |igands ; growth factors such as c - Sis ; Transcription factors such as Myb or Myc ; Extrace||u|ar signa| - regu|ated kinases ( ERK or MAPK ) ; and Wnt signa|ing proteins. The further requirement ( i. e. in addition t0 impaired p53 functi0n ) for oncogene activati0n or tum0ur suppressor inhibition ensures that on|y ce||s which tru|y undergo oncogene activation ( i. e. tumour. formati0n ) are targeted f0r ce|| death. Acc0rding to most particu|ar embodiments , the tumour or cancer to be treated is retinob|astoma. Thus , inhibitors of Dicer function are provided for use in treatment of retinob|astoma. A|though the methods can be used in vitro , e. g. to induce ce|| death in a ce|| |ine , it is particu|ar|y envisaged that they are app|ied in vivo , by inhibiting Dicer function in a subject in need thereof. Most particu|ar|y , this wi|| be done by administering an inhibitor of Dicer function to a subject in need. thereof , but gene therapy is a|so envisaged. Most typica||y , the ”subject” as used herein wi|| be an anima| , m0re particu|ar|y a mamma| ( e. g. , cats , . d0gs , horses , cows , pigs , sheep , goats , ||amas , monkeys , mice , rats , . ) , m0st particu|ar|y a human. |nhibiting Dicer function can be done in many ways. This can for instance be done by inhibiting functiona| expression of the Dicer1 gene itse|f. With ”functiona| expression” of the Dicer1 gene , it is meant the transcription and / or trans|ation of functiona| Dicer1 gene product. ”|nhibition of functionaexpression” can be achieved at three |eve|s. First , at the DNA |eve| , e. g. by removing 0r disrupting the Dicer1 gene , or preventing transcription to take p|ace ( in both instances preventing synthesis of the. Dicer1 gene product ) . Second , at the RNA |eve| , e. g. by preventing efficient trans|ati0n to take p|ace —. 10. 10. 15. 20. 25. 30. WO 2012 / 013821 PCT / EP2011 / 063233. this can be through destabi|ization of the mRNA so that it is degraded before trans|ation occurs from the transcript , or by hybridizing to the Dicer mRNA. Third , at the protein |eve| , e. g. by binding to the. Dicer protein , inhibiting its function , and / or marking the protein for degradation. |f inhibition is to be achieved at the DNA |eve| , this may be done using gene therapy to knock - out or disrupt the Dicer1 gene. As used herein , a ”kn0ck - out” can be a gene knockdown or the gene can be knocked out by a mutation such as , a point mutation , an insertion , a de|etion , a frameshift , or a missense mutation by techniques known in the art , inc|uding , but not |imited to , retrovira| gene transfer. Another way in which genes can be knocked out is by the use of zinc finger nuc|eases. Zincfinger nuc|eases ( ZFNs ) are artificia| restriction enzymes generated by fusing a zinc finger DNA - binding domain to a DNA - c|eavage d0main. Zinc finger domains can be engineered to target desired DNA sequences , which enab|es zinc - finger nuc|eases t0 target unique sequence within a comp|ex genome. By taking advantage of endogenous DNA repair machinery , these reagents can be used to precise|y. a|ter the genomes of higher organisms. m such embodiments , it wi|| be particu|ar|y envisaged that the knock - out of the Dicer1 gene is |imited to the tissue where the tumour is |ocated , and most particu|ar|y , the knock - out is |imited t0 the tum0ur. itse|f , and Dicer1 is not inhibited in the host subject. Apart from tissue - specific inhibition of Dicer1 gene product function , the inhibition may a|so be. temporary ( 0r temp0ra||y regu|ated ) . Tempora||y and tissue - specific gene inactivation may for instance a|so be achieved through the creati0n 0f transgenic 0rganisms expressing antisense RNA , or by administering antisense RNA to the subject. An antisense construct can be de|ivered , for examp|e , as an expression p|asmid , which , when transcribed in the ce|| , produces RNA that is comp|ementary to at |east a unique portion of the ce||u|ar. Dicer mRNA. A more rapid method for the inhibition of gene expression is based on the use of shorter antisense o|igomers consisting of DNA , or other synthetic structura| types such as phosphorothiates , 2 - 0 - a|ky|ribonuc|eotide chimeras , |ocked nuc|eic acid ( LNA ) ( see further in the app|ication for a more detai|ed discussion of this techno|ogy ) , peptide nuc|eic acid ( PNA ) , or morpho|inos. With the exception 0f RNA 0|igomers , PNAs and morph0|in0s , a|| 0ther antisense 0|ig0mers act in eukary0tic ce||s through the mechanism of RNase H - mediated target c|eavage. PNAs and morpho|inos bind comp|ementary DNA and RNA targets with high affinity and specificity , and thus act through a simp|e steric b|ockade of the RNA trans|ationa| machinery , and appear to be comp|ete|y resistant to nuc|ease attack. An. "antisense o|igomer” refers to an antisense mo|ecu|e or anti - gene agent that comprises an o|igomer of. 11. 10. 15. 20. 25. 30. WO 2012 / 013821 PCT / EP2011 / 063233. at |east about 10 nuc|eotides in |ength. |n embodiments an antisense o|igomer comprises at |east 15 , 18 20 , 25 , 30 , 35 , 40 , or 50 nuc|eotides. Antisense approaches invo|ve the design of o|igonuc|eotides ( either DNA or RNA , or derivatives thereof ) that are comp|ementary to an mRNA encoded by po|ynuc|eotide sequences of Dicer1. Antisense RNA may be introduced into a ce|| to inhibit trans|ation of a comp|ementary mRNA by base pairing to it and physica||y obstructing the trans|ati0n machinery. This effect is therefore stoichiometric. Abso|ute comp|ementarity , a|though preferred , is not required. A sequence "comp|ementary" to a portion of an RNA , as referred to herein , means a sequence having sufficient c0mp|ementarity t0 be ab|e t0 hybridize with the RNA , forming a stab|e dup|ex ; in the case of doub|e - stranded antisense po|ynuc|eotide sequences , a sing|e strand of the dup|ex DNA may thus be tested , or trip|ex formation may be assayed. The abi|ity to hybridize wi|| depend on both the degree of comp|ementarity and the |ength of the antisense po|ynuc|eotide sequence. Genera||y , the |onger the hybridizing po|ynuc|eotide sequence , the more base mismatches with an RNA it may contain and sti|| form a stab|e dup|ex ( or trip|ex , as the case may be ) . One ski||ed in the art can ascertain a to|erab|e degree of mismatch by use 0f standard procedures to determine the me|ting point 0f the hybridized comp|ex. O|igomers that are comp|ementary to the 5 ' end of the message , e. g. , the 5 ' untrans|ated regi0n ( UTR ) up t0 and inc|uding the AUG trans|ation initiation codon , sh0u|d work most efficient|y at inhibiting trans|ation. However , sequences comp|ementary to the 3 ' UTR of mRNAs have recent|y been shown to be effective at inhibiting trans|ation of mRNAs as we|| ( Wagner , R. ( 1994 ) Nature 372 , 333 - 335 ) . Therefore , o|igomers comp|ementary to either the 5 ' , 3 ' UTRs , or non - coding regions of a Dicer1 gene cou|d be used in an antisense approach to inhibit trans|ation of said endogenous mRNA enc0ded by Dicer1 p0|ynuc|eotides. O|igomers comp|ementary to the 5 ' UTR of said mRNA sh0u|d inc|ude the comp|ement of the AUG start codon. Antisense o|igomers comp|ementary to mRNA coding regions are |ess efficient inhibit0rs 0f trans|ation but cou|d be used in accordance with the invention. Whether designed to hybridize to the 5 ' , 3 ' or non - coding region of a said mRNA , antisense o|igomers shou|d be at |east 10 nuc|eotides in |ength , and are preferab|y o|igomers ranging from 15 to about 50 nuc|eotides in |ength. |n certain embodiments , the o|ig0mer is at |east 15 nuc|eotides , at |east 18 nuc|e0tides , at |east 20 nuc|eotides , at |east 25 nuc|eotides , at |east 30 nuc|eotides , at |east 35 nuc|eotides , at |east 4O nuc|eotides , or at |east 50 nuc|eotides in |ength. A re|ated method uses ribozymes instead 0f antisense RNA. Ribozymes are cata|ytic RNA mo|ecu|es with enzyme - |ike c|eavage properties that can be designed to target specific RNA sequences. Successfu| target gene inactivation , inc|uding tempora||y and tissue - specific gene inactivation , using ribozymes has been reported in m0use , zebrafish and fruitf|ies. RNA interference ( RNAi ) is a f0rm 0f p0st - transcripti0na| gene si|encing. The phenomenon of RNA interference was first observed and described in Caenorhobditis elegons. where exogenous doub|e - stranded RNA ( dsRNA ) was shown t0 specifica||y and p0tent|y disrupt the. 12. 10. 15. 20. 25. 30. WO 2012 / 013821 PCT / EP2011 / 063233. activity of genes containing homo|ogous sequences through a mechanism that induces rapid degradation of the target RNA. Severa| reports describe the same cata|ytic phenomenon in other 0rganisms , inc|uding experiments demonstrating spatia| and / or tempora| c0ntro| of gene inactivati0n , inc|uding p|ant ( Arobidopsis thoiiona ) , protozoan ( Tryponosomo bruceii ) , invertebrate ( Drosophiio meianogaster ) , and vertebrate species ( Danio rerio and Xenopus iaevis ) . The mediat0rs of sequencespecific messenger RNA degradation are sma|| interfering RNAs ( siRNAs ) generated by ribonuc|ease ||| c|eavage from |onger dsRNAs. Genera||y , the |ength of siRNAs is between 20 - 25 nuc|eotides ( E|bashir et a|. ( 2001 ) Nature 411 , 494 - 498 ) . The siRNA typica||y comprise a sense RNA strand and a comp|ementary antisense RNA strand annea|ed together by standard Watson Crick base pairing interactions ( hereinafter ”base paired” ) . The sense strand comprises a nuc|eic acid sequence that is identica| to a target sequence contained within the target mRNA. The sense and antisense strands of the present siRNA can comprise two comp|ementary , sing|e stranded RNA mo|ecu|es or can comprise a sing|e mo|ecu|e in which two c0mp|ementary portions are base paired and are cova|ent|y |inked by a sing|e stranded ”hairpin” area ( often referred to as shRNA ) . The term ”iso|ated” means a|tered 0r removed from the natura| state through human intervention. For examp|e , an siRNA natura||y present in a |iving anima| is n0t ”iso|ated , ” but a synthetic siRNA , or an siRNA partia||y or comp|ete|y separated from the coexisting materia|s of its natura| state is ”iso|ated.” An iso|ated siRNA can exist in substantia||y purified form , or can exist in a non native environment such as , f0r examp|e , a ce|| into. which the siRNA has been de|ivered. The siRNAs of the invention can comprise partia||y purified RNA , substantia||y pure RNA , synthetic RNA , or recombinant|y produced RNA , as we|| as a|tered RNA that differs from natura||y occurring RNA by the addition , de|etion , substitution and / or a|teration of one or more nuc|eotides. Such a|terations can inc|ude addition of non nuc|eotide materia| , such as to the end ( s ) of the siRNA or to one or more interna| nuc|e0tides 0f the siRNA , inc|uding modifications that make the siRNA resistant t0 nuc|ease. digestion. One or both strands of the siRNA of the inventi0n can a|s0 comprise a 3 ' 0verhang. A "3 ' overhang” refers to at |east one unpaired nuc|eotide extending from the 3 ' end of an RNA strand. Thus , in one embodiment , the siRNA of the invention comprises at |east one 3 ' overhang 0f from one to about six nuc|eotides ( which inc|udes ribonuc|eotides or deoxynuc|eotides ) in |ength , preferab|y from one to about five nuc|eotides in |ength , more preferab|y from one to about four nuc|eotides in |ength , and. particu|ar|y preferab|y from about one to about four nuc|eotides in |ength. m the embodiment in which both strands of the siRNA mo|ecu|e comprise a 3 ' overhang , the |ength of. the overhangs can be the same or different for each strand. |n a most preferred embodiment , the 3 ' . 13. 10. 15. 20. 25. 30. WO 2012 / 013821 PCT / EP2011 / 063233. overhang is present on both strands of the siRNA , and is two nuc|eotides in |ength. |n order to enhance the stabi|ity of the present siRNAs , the 3 ' overhangs can a|so be stabi|ized against degradation. |n one emb0diment , the overhangs are stabi|ized by inc|uding purine nuc|eotides , such as. adenosine or guanosine nuc|eotides. A|ternative|y , substituti0n of pyrimidine nuc|e0tides by modified ana|ogues , e. g. , substitution of uridine nuc|eotides in the 3 ' overhangs with 2 ' deoxythymidine , is to|erated and does not affect the efficiency of RNAi degradation. |n particu|ar , the absence of a 2 ' hydroxy| in the 2 ' deoxythymidine significant|y. enhances the nuc|ease resistance of the 3 ' overhang in tissue cu|ture medium. The siRNAs of the invention can be targeted to any stretch of approximate|y 19 to 25 contiguous nuc|e0tides in any of the target Dicer1 mRNA sequences ( the ”target sequence” ) , 0f which examp|es are given in the app|ication. Techniques for se|ecting target sequences for siRNA are we|| known in the art. Thus , the sense strand of the present siRNA comprises a nuc|eotide sequence identica| to any. contiguous stretch of ab0ut 19 to about 25 nuc|eotides in the target mRNA. The siRNAs of the invention can be obtained using a number of techniques known to those of ski|| in the art. For examp|e , the siRNAs can be chemica||y synthesized or recombinant|y produced using methods known in the art. Preferab|y , the siRNA of the invention are chemica||y synthesized using appropriate|y protected ribonuc|eoside phosphoramidites and a conventiona| DNA / RNA synthesizer. The siRNA can be synthesized as tw0 separate , comp|ementary RNA m0|ecu|es , 0r as a sing|e RNA mo|ecu|e with two comp|ementary regions. Commercia| supp|iers of synthetic RNA mo|ecu|es or synthesis reagents inc|ude Pr0|igo ( Hamburg , Germany ) , Dharmacon Research ( Lafayette , Co|o. , USA ) , Pierce Chemica| ( part of Perbio Science , Rockford , |||. , USA ) , G|en Research ( Ster|ing , Va. , USA ) , ChemGenes ( Ash|and , Mass. , USA ) and Cruachem ( G|asgow , UK ) . A|ternative|y , siRNA can a|so be expressed from recombinant circu|ar or |inear DNA p|asmids using any suitab|e promoter. Suitab|e promoters for expressing siRNA of the invention from a p|asmid inc|ude , for examp|e , the U6 or H1 RNA po| ||| promoter sequences and the cytomega|ovirus promoter. Se|ection 0f 0ther suitab|e promoters is within the ski|| in the art. The recombinant p|asmids 0f the invention can a|so comprise inducib|e or regu|atab|e promoters for expression of the siRNA in a particu|ar tissue 0r in a particu|ar intrace||u|ar environment. The siRNA expressed from rec0mbinant p|asmids can either be iso|ated from cu|tured ce|| expression systems by standard techniques , or can. be expressed intrace||u|ar|y , e. g. in breast tissue or in neurons. The siRNAs of the invention can a|so be expressed intrace||u|ar|y from recombinant vira| vect0rs. The. recombinant vira| vectors comprise sequences encoding the siRNAs of the invention and any suitab|e. 14. 10. 15. 20. 25. 30. WO 2012 / 013821 PCT / EP2011 / 063233. promoter for expressing the siRNA sequences. Suitab|e promoters inc|ude , for examp|e , the U6 or H1 RNA po| ||| promoter sequences and the cytomega|ovirus promoter. Se|ection of other suitab|e pr0moters is within the ski|| in the art. The recombinant vira| vectors of the invention can a|so comprise inducib|e or regu|atab|e promoters for expression of the siRNA in the tissue where the. tumour is |oca|ized. As used herein , an ”effective amount” of the siRNA is an amount sufficient to cause RNAi mediated degradation of the target mRNA , or an amount sufficient to inhibit the progression of metastasis in a subject. RNAi mediated degradation of the target mRNA can be detected by measuring |eve|s of the target mRNA or protein in the ce||s of a subject , using standard techniques for iso|ating and quantifying. mRNA 0r protein as described above. One ski||ed in the art can readi|y determine an effective amount of the siRNA of the invention to be administered t0 a given subject , by taking into account factors such as the size and weight 0f the subject ; the extent 0f the disease penetration ; the age , hea|th and sex of the subject ; the route of administration ; and whether the administration is regiona| or systemic. Genera||y , an effective amount 0f the siRNA 0f the invention c0mprises an intrace||u|ar concentrati0n 0f from ab0ut 1 nan0mo|ar ( nM ) to about 100 nM , preferab|y from about 2 nM to about 50 nM , more preferab|y from about 2.5 nM to. about 10 nM. |t is contemp|ated that greater or |esser amounts of siRNA can be administered. Recent|y it has been sh0wn that morpho|ino antisense o|ig0nuc|e0tides in zebrafish and fr0gs overcome the |imitations of RNase H - competent antisense o|igonuc|eotides , which inc|ude numerous non - specific effects due t0 the non target - specific c|eavage of other mRNA mo|ecu|es caused by the |ow stringency requirements of RNase H. Morpho|ino o|igomers therefore represent an important new c|ass of antisense mo|ecu|e. O|igomers of the invention may be synthesized by standard methods kn0wn in the art. As examp|es , ph0sphorothioate o|ig0mers may be synthesized by the meth0d of Stein et a|. ( 1988 ) Nuc|eic Acids Res. 16 , 3209 - 3021 ) , methy|phosphonate o|igomers can be prepared by use of c0ntro||ed pore g|ass p0|ymer supports ( Sarin et a|. ( 1988 ) Proc. Nat|. Acad. Sci. USA. 85 , 7448 - 7451 ) . Morpho|ino o|igomers may be synthesized by the method of Summerton and We||er US Patent Nos. 5 , 217 , 866 and 5 , 185 , 444. The Dicer gene pr0duct inhibitor may a|so be an inhibitor of Dicer protein. A typica| examp|e thereof is. an anti - Dicer antibody. The term ' antibody 0r ' antibodies re|ates t0 an antibody characterized as being specifica||y directed against Dicer or any functi0na| derivative thereof , with said antibodies being preferab|y mon0c|ona|. antibodies ; or an antigen - binding fragment thereof , of the F ( ab ) 2 , F ( ab ) or sing|e chain Fv type , or any. 15. 10. 15. 20. 25. 30. WO 2012 / 013821 PCT / EP2011 / 063233. type of recombinant antibody derived thereof. These antibodies of the invention , inc|uding specific po|yc|ona| antisera prepared against Dicer or any functiona| derivative thereof , have no crossreactivity t0 other proteins. The monoc|0na| antibodies 0f the inventi0n can for instance be produced by any hybridoma |iab|e to be formed according to c|assica| methods from sp|enic ce||s of an anima| , particu|ar|y of a mouse or rat immunized against Dicer or any functiona| derivative there0f , and of ce||s of a mye|oma ce|| |ine , and to be se|ected by the abi|ity of the hybridoma to produce the monoc|onaantibodies recognizing Dicer or any functiona| derivative thereof which have been initia||y used for the immunization of the anima|s. The monoc|ona| antibodies according to this embodiment 0f the invention may be humanized versions of the mouse monoc|ona| antibodies made by means of rec0mbinant DNA techno|ogy , departing from the m0use and / or human genomic DNA sequences coding for H and L chains or from cDNA c|ones coding for H and L chains. A|ternative|y the monoc|onaantibodies according to this embodiment of the invention may be human monoc|ona| antibodies. Such human mon0c|0na| antibodies are prepared , f0r instance , by means 0f human periphera| b|o0d |ymph0cytes ( PBL ) repopu|ation of severe combined immune deficiency ( SC|D ) mice as described in PCT / EP 99 / 03605 or by using transgenic non - human anima|s capab|e of producing human antibodies as described in US patent 5 , 545 , 806. A|so fragments derived fr0m these mon0c|ona| antibodies such as Fab , F ( ab ) 2 and scFv ( ”sing|e chain variab|e fragment” ) , providing they have retained the originabinding pr0perties , form part of the present inventi0n. Such fragments are common|y generated by , for instance , enzymatic digestion of the antibodies with papain , pepsin , or other proteases. |t is we|| known to the person ski||ed in the art that monoc|ona| antibodies , or fragments thereof , can be modified for various uses. The antibodies inv0|ved in the invention can be |abe|ed by an appr0priate |abe| of the enzymatic , f|uorescent , or radioactive type. m a particu|ar embodiment said antibodies against Dicer or a functiona| fragment thereof are derived from came|s. Came| antib0dies are fu||y described in WO94 / 25591 , WO94 / 04678 and in WO97 / 49805. Processes are described in the art which make it possib|e that antibodies can be used to hit intrace||u|ar targets. Since Dicer is an intrace||u|ar target , the antib0dies or fragments thereof with a specificity f0r Dicer must be de|ivered into the ce||s. One such techno|ogy uses |ipidati0n 0f the antibodies. The |atter meth0d is fu||y described in WO94 / 01131 and these methods are herein incorporated by reference. Another method. is by fusing the antibody to ce|| - penetrating peptides ( Chen and Harrison , Biochem Soc Trans. 2007 ) . Antibodies binding to Dicer are commercia||y avai|ab|e , e. g. from Abcam , Santa Cruz biotechno|ogy , . Sigma - A|drich and the |ike. 16. 10. 15. 20. 25. 30. WO 2012 / 013821 PCT / EP2011 / 063233. |f the tumour is |ocated in the brain , the inhibitor shou|d be ab|e to pass the b|ood - brain barrier. Techno|ogies of modifying antibodies to pass the b|ood - brain barrier are we|| known to the ski||ed. person. Other inhibitors of Dicer inc|ude , but are not |imited to , peptide inhibitors of Dicer , peptide - aptamer ( Tomai et a|. , J Bi0| Chem. 2006 ) inhibit0rs of Dicer , and protein interferors as described in. WO2007 / 071789 , incorporated herein by reference. Sma|| mo|ecu|e inhibitors , e. g. sma|| organic m0|ecu|es , and 0ther drug candidates can be obtained , for. examp|e , from combinatoria| and natura| product |ibraries. According to particu|ar|y envisaged embodiments , however , Dicer function is inhibited downstream of Dicer , by inhibiting one or more miRNAs that are upregu|ated by Dicer in ce||s where p53 function is impaired. As wi|| be detai|ed in the examp|es section , specific miRNAs that fa|| under this category are the members of the po|ycistronic miR 17 - 92 c|uster. |n some settings ( |ike for instance retinob|astoma ) upregu|ation of these miRNAs means that they are present in p53 deficient ce||s , whereas they are not expressed in contro| ce||s ( e. g. retinob|asts ) . Thus , inhibition of these miRNAs can be d0ne in tissues. where they are not norma||y expressed , thereby reducing the risk of side effects. |nhibiti0n 0f 0ne 0r m0re 0f the miRNAs upregu|ated by Dicer in ce||s where p53 is c0mpr0mised can be done at the DNA or RNA |eve| , as described for Dicer above. ( |nhibition at the protein |eve| is not feasib|e since miRNAs are non - pr0tein c0ding RNAs ) . Particu|ar|y suited for inhibition 0f miRNAs are |ocked nuc|eic acids ( LNAs ) or antagomirs. A |ocked nuc|eic acid , often referred to as inaccessib|e RNA , is a modified RNA nuc|eotide. The ribose m0iety 0f an LNA nuc|e0tide is m0dified with an extra bridge c0nnecting the 2 ' oxygen and 4 ' carbon. The bridge "|ocks" the ribose in the 3 ' - endo ( North ) conformation , which is often found in the A - form of DNA or RNA. LNA nuc|eotides can be mixed with DNA or RNA bases in the o|igonuc|eotide whenever desired. Such o|igomers are commercia||y avai|ab|e ( e. g. from Exiqon ) . The |ocked ribose conformation enhances base stacking and backbone pre - organization. This significant|y increases the thermastabi|ity ( me|ting temperature ) of o|igonuc|eotides. |mportant|y , LNA incorporation genera||y improves mismatch discriminati0n c0mpared to unm0dified reference 0|ig0nuc|eotide , and LNA mediates high - . affinity hybridization by using the Watson - Crick ru|es without compromising base pairing se|ectivity. LNA o|igonuc|eotides are readi|y transfected into ce||s using standard techniques : they are sequence - . specific and non - toxic , and show improved nuc|ease resistance , which make them high|y usefu| for. 17. 10. 15. 20. 25. 30. WO 2012 / 013821 PCT / EP2011 / 063233. powerfu| and se|ective antisense - based si|encing. Hence , LNA o|igonuc|eotides are unique|y suited for mimicking RNA structures and for miRNA targeting both in vivo and in vitro. Such LNA - based RNA antagonists have unusua||y high p0tency , biostabi|ity , and duration of action. See thure Methods - 4 , . ( 2007 ) for more background on miRNA knockdown using LNA probes. Antagomirs are another examp|e of chemica||y engineered o|igonuc|eotides that can be used to si|ence endogenous microRNA. An antagomir is a sma|| synthetic RNA that is perfect|y comp|ementary to the specific miRNA target with either mispairing at the c|eavage site of Ago2 or some sort of base modification to inhibit Ago2 c|eavage. Usua||y , antagomirs have some sort of modification to make it more resistant to degradation. |t is unc|ear how antagomirization ( the process by which an antagomir inhibits miRNA activity ) operates , but it is be|ieved to inhibit by irreversib|y binding the miRNA. Antagomirs are n0w used as a method to constitutive|y inhibit the activity of specific miRNAs ( 39 ) . One c|ear advantage with respect to siRNA techno|ogy is that antagomirs did not induce an immune. resp0nse. According to a specific embodiment , inhibition of Dicer function means inhibition of one or more of the fo||0wing miRNAs : miR - 17 , miR - 18a , miR - 19a , miR - 20a , miR - 19b - 1 , and miR - 92 - 1. A|though inhibiti0n of one of these miRNAs in ce||s in which p53 function is impaired a|ready resu|ts in ki||ing of these ce||s , it is envisaged that more than 0ne of these miRNAs is inhibited , e. g. a|| members of the same miRNA fami|y ( see ab0ve ) , or a|s0 members of a para|og gene c|uster , 0ther fami|y members of this gene c|uster , and so on , may be inhibited as we||. |nhibitors of these miRNAs may be used in treatment of. cancer , particu|ar|y in retinob|astoma. A|though fu|| inhibition of a given miRNA is particu|ar|y envisaged , partia| inhibition may have. beneficia| effects as we|| ( e. g. at |east 25% inhibition , at |east 50% inhibition or at |east 75% inhibition ) . As Dicer function ( and miRNA contro| ) is important , inhibition of Dicer function is particu|ar|y envisaged to be tempora||y and / 0r spatia||y regu|ated , rather than just systemic inhibiti0n. Acc0rding to particu|ar embodiments , inhibition wi|| not be done during prenata| deve|opment. According to further particu|ar embodiments , inhibition of Dicer function wi|| be restricted in time : after the ce||s in which p53 function is compromised have died , Dicer function wi|| no |onger be inhibited. According to other particu|ar embodiments , inhibition of Dicer function wi|| on|y be done in the tissue where ce||s with compromised p53 function are |ocated ( in practice : the tumour itse|f or the tissue where a tum0ur is |ocated ) . A non - |imiting examp|e hereof is in the case of retinob|astoma , where. inhibitors of Dicer function can be administered direct|y into the eye. A further benefit hereof is that. 18. 10. 15. 20. 25. 30. 35. WO 2012 / 013821 PCT / EP2011 / 063233. this direct administration approach faci|itates inhibition at the RNA |eve| — indeed , in the case of systemic inhibition , stabi|ity of RNA inhibitors is often an issue , but if time and |ocation of inhibition can. be restricted , this a||ows more efficient inhibiti0n. As mentioned , the methods provided herein induce ce|| death in ce||s wherein p53 function is compromised. The way in which p53 function is compromised is in fact not essentia| to the invention. |n many tumours , for instance , p53 function is compromised as a resu|t of one or more mutations. However , it is particu|ar|y envisaged herein that p53 function may a|so be compromised by functionadysregu|ation that is not the resu|t of mutation in p53. ”Functiona| dysregu|ation” as used herein typica||y means that p53 function is impaired as the resu|t of d0wnregu|ati0n of |eve|s of functiona||y active p53 protein. This may for instance be the resu|t of mutations in other components of the p53 pathway that u|timate|y resu|t in |owering of the |eve|s of functiona| p53. As a non - |imiting examp|e , p53 function is compromised in retinob|astoma as a resu|t of amp|ification of the MDMX gene , and not. due t0 mutations in p53 itse|f ( 13 ) . |t is to be understood that a|though particu|ar embodiments , specific configurations as we|| as materia|s and / or mo|ecu|es , have been discussed herein for ce||s and methods according to the present invention , various changes or modifications in form and detai| may be made without departing from the scope and spirit of this invention. The fo||owing examp|es are provided to better i||ustrate particu|ar embodiments , and they shou|d not be considered |imiting the app|ication. The app|ication is |imited on|y by the c|aims. Note that , due to the requirements of b|ack and white reproducibi|ity of the. figures , some experimenta| data are not shown in the figures , but can be obtained upon request. Examp|es. Examp|e 1. Dicer1 is a synthetic |etha| partner of p53. . |n order to test whether Dicer is required for retinob|astoma formation we conditiona||y inactivated Dicer1 in mice that deve|0p aggressive and invasive retin0b|astoma ( 10 ) . Chx10Cre ; Rb ' °X / ' °X ; p107” mice ( thereafter referred to as DKO mice ) deve|op ear|y hyperpro|iferative |esions ( 11 ) , which on|y rare|y g0 on to become aggressive and invasive tumours. Acc0rding|y , these mice deve|op on|y retinob|astoma with de|ayed and variab|e kinetics ( Figure 1A ) . As previous|y reported ( 10 ; 12 ) , . conditiona| inactivation of p53 on this sensitized background ( Chx10Cre ; Rb ' °X / ' °X ; p107 / j p53 ' °X / ' °X , . referred to as the TKO mice ) |eads t0 rapid formation of visib|e retin0b|ast0ma in virtua||y a|| mice 19. 10. 15. 20. 25. 30. WO 2012 / 013821 PCT / EP2011 / 063233. ana|yzed ( 122 out of 129 ) . On average it takes 10O days for these mice to deve|op visib|e tumours ( Figure 1A ) . Moreover , whi|e DKO mice on|y ever deve|op uni|atera| tumours more than 80% of TKO mice ( 97 out of 122 ) deve|0p bi|atera| retinob|astoma with c|ear evidence of anterior chamber invasion. |n addition , metastatic tumours that had invaded |oca| tissues outside of the eye through the optic nerve are on|y observed in TKO mice ( data not shown ) . |n sharp c0ntrast to this very aggressive and near|y 100% penetrant phenotype , none of the Chx10Cre ; Rb ' ”X / ' °X ; p107 / ' ; p53"X / ' °X ; Dicer1 ' °X / "X ( referred to as QKO ) mice ana|yzed ( 19 out of 19 ) deve|oped visib|e retinob|astoma within their first year of |ife ( Figure 1A ) . This striking resu|t argues in favour of a critica| r0|e for Dicer in the formati0n of. retinob|astoma. Unexpected|y , retinae of QKO mice have a norma| cytoarchitecture ( Figure 1B ) . The retina| |aminar organization of DKO mice is s|ight|y disrupted due t0 foca| expansion of immature ce||s from the inner nuc|ear |ayer ( |NL ) and their protrusion through the outer p|exiform |ayer ( OPL ) , in agreement with a previous report ( 13 ) . Additiona||y , defects in the maturation 0f the r0d ph0toreceptors |ead to a hypoce||u|ar outer nuc|ear |ayer ( ONL ) ( Figure 1B ) . This phenotype is exacerbated upon |oss of p53 , and tumours rapid|y deve|op in retinae of TKO mice. |n c0ntrast , no evidence of tum0ur formati0n was seen in any of the QKO retinae examined. More surprising|y , dysp|astic |esions were absent in these retinae and the ONL appeared intact ( Figure 1B ) . We assessed ce|| pro|iferation in retinae at P14 , by which time retin0genesis is n0rma||y comp|ete. As previous|y reported ( 11 ; 8 ) , we f0und extensive BrdU incorporation and numerous Ki67 - positive ce||s in DKO retinae ( Figure 1C ) . This phenotype was significant|y exacerbated in TKO retinae and BrdU - and Ki67 - positive ce||s were found in a|| ear|y dysp|astic |esions and |ate ( i. e. P200 ) retinob|astoma tumours ( data not shown ) . Consistent with the absence of dysp|astic |esions we found no evidence of ectopic ce|| pro|iferation in QKO retinae from P14 onwards. |n fact , the retina| cytoarchitecture of QKO mice was indistinguishab|e from wi|d - type retinae at a|| stages and in a|| mice ana|yzed. The integrity 0f the retina| cytoarchitecture was further confirmed by ana|yzing the proportion and distribution of the retina| ce|| types in the QKO retinas and. contr0|s ( Figure 1C and data not shown ) . As it is un|ike|y that |oss of Dicer1 comp|ete|y reverts the transformed Rb1 / p107 / p53 - deficient retinob|asts into phenotypica||y norma| ce||s , we hypothesized that bia||e|ic |oss of Dicer1 compromises the surviva| of the tumour initiating ce||s. Because of the mosaicism exhibited in the Chx10Cre transgenic |ine ( 14 ) , there remained a possibi|ity that Cre - positive ce||s , and therefore the Dicer1 deficient ce||s , might be e|iminated and / or outcompeted by the remaining Dicer1 wi|d - type Crenegative ce||s without causing any obvious retina| morpho|ogica| defects. |n order to fate map the. Dicer1 deficient ce||s we took advantage of the green f|uorescent protein ( GFP ) and a|ka|ine. 20. 10. 15. 20. 25. 30. WO 2012 / 013821 PCT / EP2011 / 063233. phosphatase ( AP ) reporter genes present in the BAC Chx10 transgenic construct ( 14 ; 15 ) . GFP expression accurate|y marks subsets of Chx10 - positive ce||s that underwent Cre - mediated recombination ( 15 ) . m adu|t retinae GFP is detected in a subset of postmitotic bipo|ar and Mu||er ce||s , which are |ocated within the |NL , at the interface between the |NL and OPL ( Figure 2A ) . |mportant|y , we found that Dicer is dispensab|e for the expansion , ce|| fate specification and differentiation 0f retina| progenitor ce||s since GFP - positive ce||s were identified in the |NL of Chx10Cre ; Dicer1 ' °X / ' °X retinae ; moreover , these retinae were indistinguishab|e from those of wi|d - type |ittermates ( Figure 4 ) . Consistent with a previous study ( 16 ) foca| and progressive retina| degeneration was observed in a few o|der mice suggesting that Dicer might be required for the surviva| of some termina||y differentiated neurona| ce|| popu|ations. However , the penetrance of this phenotype was extreme|y |ow ( 1 out 0f 11 mice examined ) . Critica||y , GFP - positive ce||s cou|d a|so be identified in retinae of Chx10Cre ; Rb ' °X / "X ; . p107 / 3 Dicer1 ' °X / ' °X ( Figure 2A ) indicating that Dicer deficiency does not compromise the viabi|ity of the. retina| progenit0rs on either wi|d - type or Rb / p107 - deficient backgrounds. To further demonstrate the presence of Dicer - deficient ce||s in Chx10Cre ; Dicer1"” ' / ' °X and. Chx10Cre ; Rb ' °X / ' °X ; p107 / j Dicer1 ' °x / ' °X retinae we determined mature miRNAs expression |eve|s in FACSsorted GFP - positive ce||s from three retinae of each genotype. Consistent with the |oss of Dicer function we observed a dramatic g|oba| shut - down / down - regu|ation in steady - state miRNA |eve|s in a|| samp|es ana|yzed compared to the |eve|s in Chx10Cre ; Dicer1 + / + and Chx10Cre ; Rb ' °X / ' °X ; p107 / ' ; Dicer1 + / ' . retinae ( data not shown ) . This ana|ysis supports the presence of Dicer - deficient ce||s in these retinae. |n sharp contrast , GFP - positive ce||s cou|d not be identified in QKO adu|t retinae ( Figure 2A ) , indicating that the Chx10Cre / GFP - p0sitive ce||s are specifica||y e|iminated and / 0r segregated out during deve|opment upon inactivation of both Dicer1 and p53. To substantiate this observation we dissociated QKO and contro| adu|t retinae and scored individua| GFP - positive ce||s in 3 independent samp|es for each genotype by FACS. This ana|ysis confirmed the presence of GFP - positive ce||s in Chx10Cre ; Dicer1 ' °X / ' °X and Chx10Cre ; Rb ' °X / ' °X ; p107 / j Dicer1 ' °X / ' °X but not in QKO retinae ( data not shown ) . C0nsistent|y , AP rep0rter activity was detected in a|| Chx10Cre ; Rb ' °X / ' °X ; p107 / j Dicer1 ' °X / ' °X adu|t retinae ana|yzed ( Figure 2B ) . |n contrast , no activity cou|d be detected in 3 out of 4 QKO adu|t retinae ana|yzed and very few positive - ce||s were identified in the remaining samp|e , most |ike|y due to incomp|ete Cre - mediated recombination of at |east one of the f|oxed |oci ( Figure 28 ) . m keeping with the above observations , PCR - based genotyping confirmed Cre - mediated recombination of the conditiona| Dicer1 a||e|e in Chx10Cre ; Rb ' °X / ' °X ; p107 / ' ; Dicer1 ' °X / ' °X but not in QKO adu|t retinae ( P20 ) ( Figure 2C ) . Consistent with the mosaicism exhibited in the Chx10Cre transgenic |ine the non - . iox / iox. recombined Dicer1 a||e|e remained detectab|e in a|| Dicer1 samp|es ana|yzed. 21. 10. 15. 20. 25. 30. WO 2012 / 013821 PCT / EP2011 / 063233. To exc|ude that the |ack of Cre - positive ce||s in QKO adu|t retinae is due to compromised Cre expression we performed who|e - mounts AP staining on E11.5 mutant and contro| embryos , a deve|opmenta| stage at which the Chx10 - positive retina| progenit0r ce||s are first detected. AP reporter activity was detected in the retina of a|| Chx10Cre - positive embryos , inc|uding QKO , but as expected not in Chx10Cre - negative embryos ( data not shown ) . The presence of the mutant ce||s in the retina of. QKO E11.5 embryos was further confirmed using the GFP reporter ( data not shown ) . As mutant ce||s are detected in QKO retinae at E11.5 but not in adu|t mice , we searched for evidence of apoptotic ce|| death as a possib|e cause for their e|imination from E11.5 onwards ( data not shown ) . A|| GFP - positive ce||s were negative for the activated - form of caspase - 3 ( casp - 3 * ) in Chx10Cre ; Rb ' °X / ' °X ; p107 / ' ; Dicer1 ' °X / ' °X retinae at a|| stages ana|yzed ( E11.5 , E135 and E14.5 ) . |n contrast , GFP / Casp - 3 * - doub|e positive ce||s were detected as ear|y as E11.5 in QKO retinae ( data not shown ) . At E14 , 5 , GFP - positive ce||s ( as we|| as AP - reporter activity ) were on|y detected in Chx10Cre ; Rb ' °X / ' °X ; p107 / ' ; Dicer1 ' °X / ' °X , but not QKO , retinae ( data not shown ) . These findings indicate that ap0ptosis contributes to the rapid e|imination of Rb / p107 / Dicer / p53 - mutant ce||s during deve|opment and that Dicer1 is required for the surviva| of Rb1 / p107 - deficient retina| progenit0r ce||s in which p53 function is disab|ed but not in ce||s with an intact p53 pathway. Co||ective|y , our resu|ts demonstrate that inactivation of Dicer and p53 is synthetica||y |etha| to susceptib|e ( Rb / p107 - deficient ) ce||s. To the best. 0f 0ur kn0w|edge , this is the first genetic evidence of an in vivo synthetic |etha| interaction with p53. Examp|e 2. Dicer effects on surviva| mediated via miR 17 - 92 c|uster. . These data indicate that pharmaco|ogica| inactivati0n 0f Dicer enzymatic activity may represent an attractive therapeutic moda|ity , at |east in the context of retinob|astoma. However , we have previous|y shown that partia| Dicer1 inactivation enhances rather than inhibits retin0b|astoma formation ( 8 ) . We therefore set out to investigate the under|ying mo|ecu|ar basis for tumour suppression e|icited by comp|ete Dicer1 inactivation in order to exp|ore more appropriate therapeutic approaches. We reas0ned that a subset 0f miRNAs , the maturati0n 0f which depends on Dicer function , is |ike|y to promote Dicer1 - mediated surviva| of Rb / p107 / p53 - deficient retinob|astoma ce||s. To search for such miRNAs we profi|ed miRNA expression in P21 retinae from wi|d—type ( Cre - negative ) , DKO and dissected tumour materia| from TKO mice. This ana|ysis identified a set of 102 miRNAs that are significant|y up - regu|ated in the TKO tumours ( Tab|e 1 and data not shown ) . To find corre|ates of the mouse data in human tumours , we a|so profi|ed miRNA expression in 30 different human primary retinob|ast0mas. 68 miRNAs were significant|y up - regu|ated in retinob|astoma compared to norma|. human retinae ( Tab|e 2 and data not shown ) . Cross - species comparison identified 25 miRNAs that were. 22. 10. 15. 20. 25. 30. WO 2012 / 013821 PCT / EP2011 / 063233. up - regu|ated in both mouse and human tumours ( Tab|e 3 ) . Striking|y , 12 of them are members of the known oncogenic miR - 17 - 92 and 106b - 25 / miR - 106a - 92 para|ogue c|usters ( 17 , 18 ) . Consistent|y , hierarchica| c|ustering of a|| RB cases and norma| retinae based on miRNA expression sing|ed out a|| members of these c|usters as being dramatica||y up - regu|ated in a|| mouse and human tumours ana|yzed ( Figure 3A and data not shown ) . Sp0radic retinob|astomas are often more advanced than tumours from patients with germ|ine RB1 mutations , main|y due to the fact that they tend to be diagnosed significant|y |ater ( 19 ) . |nteresting|y , miR - 17 - 92 expression |eve|s are significant|y higher in sporadic retinob|ast0ma samp|es ( heatmap data not shown ; Mann - Whitney P<0 , 05 ) . To exp|ore the potentia| causes of miRNA deregu|ation in human retinob|astoma we |ooked for genomic aberrations using a 44K o|igonuc|eotide array which was specifica||y designed to inc|ude regions harbouring miRNA genes. |n addition to identifying previous|y reported retinob|astomaassociated genomic aberrations ( 1q gain and 6p22 gain were frequent|y seen in our cohort ) focaamp|ification of the miR - 17 - 92 |ocus , which |ies on chromosome 13 , was found in one patient ( data not shown ) . Another patient had a who|e chromosome 13 gain and 3 patients had copy number gains inc|uding the miR - 17 - 92 c|uster but , important|y , not the c|ose|y |inked Rb - 1 |ocus. miR - 17 - 92 copy number gains were found in 17% 0f the patients ( 5 out 0f 29 cases ana|ysed ) . M0reover , whi|e the Rb - 1 |ocus was de|eted in 21% of cases ( 6 / 29 ) this de|etion never inc|uded the c|ose|y |inked miR - 17 - 92 |ocus. This ana|ysis theref0re indicates that up - regu|ation 0f the miR - 17 - 92 c|uster is , at |east in a proportion of retinob|astoma cases , a direct consequence of increased gene copy number. Since transcription of miR - 17 - 92 is positive|y regu|ated by the E2Fs ( 20 ) and negative|y regu|ated by p53 ( 21 ) , deregu|ation of their transcripti0na| activities may a|so account for miR - 17 - 92 overexpression in retinob|astoma. Regard|ess of the under|ying mechanism , our data demonstrate that the miR17 - 92 c|uster is overexpressed in 100% of retinob|astomas ana|ysed. The miR17 - 92 c|uster is a|so expressed at very high |eve|s in the human retinob|astoma ce|| |ines Rb15 , WER| - Rb1 and Y - 79 in which both the Rb and p53 tumour suppressor pathways are inactivated and / or compr0mised ( 12 ) . Data f0r miR - 17 are sh0wn in figure 3B. To exp|ore if the viabi|ity 0f the retin0b|astoma ce||s is dependent on functiona| miR - 17 - 92 expression , each miRNA 0f the c|uster was inhibited by transient transfection of miRNA - inhibitors. |nhibition of a|| individua| miRNAs induced a significant decrease in ce|| viabi|ity as measured by MT| ' ( Figure 3C ) and caspase - g|ow ( data not shown ) assays. The apoptotic effects of miR17 - 92 knockdown were evident in the two ce|| |ines tested , Y79 and WER| - RB1 ( Figure 3C and data not shown ) . C0nc|usion. These resu|ts |ead us to propose the fo||owing working mode| for the ro|e of Dicer inactivation - . induced tum0ur suppression ( Figure 3D ) . First , comp|ete Dicer1 inactivation does not affect surviva|. 23. WO 2012 / 013821 PCT / EP2011 / 063233. and / or differentiation of retina| progenitor ce||s , even in ce||s experiencing oncogenic stress e|icited as a resu|t of Rb inactivation. Second , Dicer and p53 inactivation are synthetica||y |etha| to ce||s harbouring a deficient Rb pathway. Given that the Rb and p53 pathways are inactivated in m0st human cancers , our observations ( i ) provide a rationa| exp|anation for the se|ection against homozygous |oss of DlCER1 in human cancer ( 22 ) and ( ii ) identify a nove| pharmaco|ogica| mode of tumour—type - specific intervention. Third , inactivation of members of the miR - 17 - 92 c|uster is sufficient to ki|| human retinob|astoma ce||s and , important|y , we show that it does so in a se|ective manner. |ndeed , inactivati0n of Dicer , and consequent|y processing of the pre - miRs , in norma| retinob|asts does not affect their surviva| and function. The miR - 17 - 92 c|uster is in fact not norma||y expressed in these ce||s. Therapeutic si|encing of another pro - oncogenic miR , miR10b , was recent|y shown to successfu||y suppress metastasis in a mouse mammary tumour mode| ( 23 ) . Our resu|ts ca|| for the deve|opment and optimization of miR17 - 92 inhibitors for the treatment of Retinob|astoma patients. |mportant|y , in the context of retinob|astoma there wi|| be no need for systemic exposure t0 the miR - inhibitors thus reducing the potentia| side effects of such treatment in other tissues / organs. Retinob|ast0mas cou|d be. simp|y treated by sub - conjuctiva| injection of the miRNA - inhibitory mo|ecu|es. Tab|e 1. Differentia| miRNA expression in mouse tumors. Tumour vs. norma| retina Tumour vs. DKO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . miRNA fo|d change p va|ue fo|d change p va|ue. |et - 7a O.734301438 O.273072124 0.895076406 O.691557694 |et - 7a * 5.500790963 0.01960028 5.415980315 0.021881848 |et - 7b 3.535319648 0.010370294 2.780131413 0.044361147 |et - 7C 3.359480225 0.029237804 2.438476587 0.068784999 |et - 7c - 1 * 4.741319935 O.12659217 3.893437575 O.169852634 |et - 7d 1.234074148 O.297825824 1.172828306 O.456789172 |et - 7d * O.369079986 0.088943386 0.530989595 0.119000858 |et - 7e 1.284143189 O.16447827 1.396422488 O.14130197 |et - 7f O.944737925 O.776895779 1.00984217 0.97561554 |et - 7g 1.135094436 0.376289911 1.315125134 O.258536706 |et - 7g * 2.633175622 0.103630898 4.144327923 0.072340757 |et - 7i 1.946962814 0.047999992 1.303389019 O.239329412 |et - 7i * 1.393543863 O.564728821 2.186352712 O.272723927 miR - 1 O.793125549 O.828543422 O.953113488 O.97561554 miR - 100 2.12461644 0.299729218 1.60608008 0.514352631 miR - 101 2.426418798 0.028992766 2.840896611 O.132338746 miR - 101b 2.288168687 0.031233542 2.551209713 O.150229027 miR - 103 1.304877384 0.395284529 1.114962608 O.755335075 miR - 106a 51.88732466 0.009211953 22.434866 0.044361147 miR - 106b 6.475493206 0.008756512 5.22690581 0.037187565 miR - 106b * 9.844896779 0.005663749 7.645337351 0.093681498 miR - 107 0.516511513 0.076016013 0.489836945 0.074673743 miR - 10a 3.007375768 0.109853962 3.007375768 0.120591568 miR - 122 2.411861573 0.068257972 1.876264315 O.193963821 miR - 124 * O.385164461 0.092967467 2.18350663 O.234819943 miR - 124a O.201127661 0.013065457 0.422317566 0.090516995 miR - 125a - 3p O.934740784 O.868020022 0.878067241 O.755335075. . 24. . WO 2012 / 013821. PCT / EP2011 / 063233. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . miRNA fo|d change p va|ue fo|d change p va|ue miR - 125a - 5p 1.596537378 0.081265395 1.390863409 0.169906827 miR - 125b 1.088496483 0.886038235 0.818446203 0.769067534 miR - 125b - 1 * 1.770265293 0.457427124 0.831135341 0.830086967 miR - 125b * 5.297581936 0.06229364 4.625811288 0.084606159 miR - 126 2.66222575 0.029237804 4.879164064 0.044174334 miR - 126 * 1.811762582 0.088943386 3.263671823 0.048681312 miR - 127 0.721441505 0.456333899 0.70710633 0.514352631 miR - 127 - 5p 0.650588359 0.370899476 1.057760247 0.939920721 miR - 128a 0.682300808 0.388937085 0.654503545 0.398452113 miR - 129 0.112886294 0.009114302 0.16193731 0.031840324 miR - 129 - 3p 0.096027627 0.131817586 0.137454408 0.184663709 miR - 130a 1.714212739 0.009211953 1.992597859 0.008284863 miR - 130b 0.584223581 0.218057936 0.76690631 0.545897969 miR - 130b * 0.648138518 0.35055361 0.928990552 0.884258382 miR - 132 1.610414979 0.071921844 1.995821337 0.045032645 miR - 133a 1.209649917 0.85756787 1.341565656 0.784560308 miR - 133b 0.819424977 0.816788557 0.913055327 0.927148592 miR - 134 2.533648981 0.082752178 2.182816839 0.13242275 miR - 135a 0.947012745 0.896990567 0.711812659 0.514352631 miR - 135b 2.695144104 0.056906094 2.055214293 0.101841409 miR - 136 1.454762185 0.369116137 1.824672752 0.339420243 miR - 136 * 0.888645206 0.86965276 1.195340751 0.846473322 miR - 137 4.292698447 0.029314715 3.841261671 0.062517807 miR - 138 0.774582196 0.404055957 0.734488596 0.399768272 miR - 138 * 1.066972749 0.896990567 1.277755155 0.688990152 miR - 139 - 5p 0.931787036 0.868020022 0.797496216 0.65840633 miR - 140 2.735000626 0.108061678 3.059077333 0.093644648 miR - 140 - 3p 2.747517645 0.110169748 3.598233545 0.081908469 miR - 141 1.910039874 0.22554139 1.910039874 0.241987116 miR - 141 * 0.739060349 0.338434293 0.820596646 0.305973764 miR - 142 - 3p 16.58444981 0.009211953 4.825204192 0.049181724 miR - 142 - 5p 1.764389659 0.251822108 1.764389659 0.26818725 miR - 143 0.944622517 0.867361688 1.985466353 0.272723927 miR - 145 0.874432289 0.437037218 2.019517987 0.272723927 miR - 146a 11.11818391 0.002195316 3.384791564 0.169906827 miR - 146b 7.609411663 0.025658662 3.48580934 0.156890504 miR - 146b * 5.421234813 0.034057514 3.357236673 0.272723927 miR - 148a 1.419358221 0.172214176 1.550539374 0.170193706 miR - 148b 0.496591566 0.019160538 0.701865297 0.26072901 miR - 149 1.413545671 0.553677869 1.070146451 0.927148592 miR - 150 1.077543601 0.850026351 1.605402811 0.421756911 miR - 151 1.443399753 0.120638185 1.95622999 0.045032645 miR - 152 1.8558237 0.077264211 2.100334454 0.07594739 miR - 153 0.973132222 0.918184799 1.012256895 0.97561554 miR - 154 0.413246188 0.350076141 0.269319659 0.048681312 miR - 154 * 1.463869297 0.350076141 1.409677841 O.42548775 miR - 155 5.933582476 0.015061298 5.046847506 0.13464374 miR - 15a 0.79465405 0.365620036 1.596374249 0.140793064 miR - 15a * 6.458406117 0.015061298 7.178543943 0.032975304 miR - 15b 5.453081609 0.042476325 4.601895305 0.119290587 miR - 15b * 63.19234564 0.004880222 54.2892756 0.071472927 miR - 16 3.03333113 0.031145366 5.157747255 0.021881848 miR - 16 * 33.00514612 0.004880222 18.22452737 0.068784999 miR - 17 47.58305778 0.003001541 21.55266196 0.048681312 miR - 17 * 7.05075498 0.028402843 11.1288388 0.021881848 miR - 181a 0.389439038 0.033900585 0.37898382 0.045032645 miR - 181C 0.541217538 0.149815607 0.545253329 0.169906827 miR - 182 0.048317007 0.172214176 0.275678755 0.514352631 miR - 183 0.01589759 0.113284896 O. 106294068 0.297958323. . . . . . 25. . WO 2012 / 013821. PCT / EP2011 / 063233. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . miRNA fo|d change p va|ue fo|d change p va|ue miR - 183 * 0.055440811 0.19087909 0.266099108 0.514352631 miR - 184 0.702490237 0.518954901 0.709519298 0.585727041 miR - 185 1.293797425 0.218834142 1.097829361 0.664490289 miR - 186 7.494097062 0.002195316 6.952665003 0.008284863 miR - 186 * 8.533299375 0.015061298 9.996246045 0.016693972 miR - 187 1.027614389 0.980198027 1.008589011 0.993935867 miR - 188 - 5p 0.667991583 0.469533282 1.01831524 0.977738661 miR - 18a 72.27794902 0.002806999 20.79573463 0.086537932 miR - 18a * 7.461352046 0.023256995 5.850095442 0.03182938 miR - 190 0.608081033 0.456333899 0.642448143 0.615865824 miR - 190b 1.50113164 0.868020022 1.896581777 0.813855461 miR - 191 1.517794263 0.003001541 2.736758872 0.001019177 miR - 191 * 1.033571955 0.816788557 1.895671408 0.031840324 miR - 192 2.614714927 0.034279558 2.872128728 0.070328146 miR - 193 * 1.154246211 0.818492942 1.444852692 0.621086022 miR - 193a - 3p 3.384089903 0.126516653 2.558701214 0.22188577 miR - 193b 2.205458831 0.104792913 1.333084513 0.456789172 miR - 194 1.527037153 0.176652403 1.687718055 0.239130081 miR - 195 3.362819079 0.007422321 2.881220841 0.021881848 miR - 197 1.171123896 0.456333899 1.171123896 0.514352631 miR - 199a - 3p 3.291284517 0.092894954 3.076816693 0.104739682 miR - 199b 2.038745576 0.177764775 2.402577967 0.14130197 miR - 19a 9.927933234 0.010215094 13.18852662 0.021881848 miR - 19a * 1.670580162 0.19087909 1.670580162 0.208481167 miR - 19b 10.94909897 0.009211953 13.99269546 0.021881848 miR - 200b 2.76435281 0.299729218 2.76435281 0.32227898 miR - 200C 1.550928585 0.331120109 1.550928585 0.358211754 miR - 202 1.350339304 0.504186314 1.261854694 0.664490289 miR - 203 * 1.563018795 0.224988858 1.563018795 0.241480188 miR - 204 0.720597805 0.307830726 0.793270468 0.552196956 miR - 205 15.45435663 0.031233542 10.87447684 0.045032645 miR - 206 0.214325624 0.131817586 0.220662084 0.14130197 miR - 20a 36.49125415 0.009367224 14.18148047 0.082523815 miR - 20a * 12.64508979 0.031145366 12.64508979 0.045032645 miR - 20b 45.10422985 0.009778614 17.69737212 0.072340757 miR - 21 1.530207798 0.241105342 2.11482555 0.098003228 miR - 21 * 2.178372553 0.273587458 2.178372553 0.289295829 miR - 210 1.068042579 0.868020022 1.898411281 0.15264265 miR - 211 0.101938501 0.00269215 0.184349707 0.148151099 miR - 212 2.095296625 0.121654045 2.929655266 0.032615321 miR - 214 1.249048156 0.338434498 1.249048156 0.368787367 miR - 214 * 6.444509298 0.087108433 8.736090098 0.086350539 miR - 215 5.7967875 0.057413845 5.772739652 0.021881848 miR - 216b 0.449015451 0.746146781 0.456152379 0.76428247 miR - 217 0.917777961 0.933056246 1.095641499 0.955360333 miR - 218 3.359471008 0.123495218 4.383785358 0.111992679 miR - 218 - 1 * 1.216832772 0.299729218 1.039949396 0.856459229 miR - 218 - 2 * 5.394466383 0.126740139 5.394466383 0.14130197 miR - 22 0.726056134 0.243229591 1.468079822 0.549700638 miR - 22 * 0.439713022 0.053252118 0.714149279 0.517563385 miR - 221 1.439574378 0.404055957 1.098312104 0.857942498 miR - 222 8.233459518 0.002477929 5.760855863 0.02196098 miR - 224 1.616805345 0.128099157 2.424040963 0.283239022 miR - 23b 0.549417777 0.131817586 0.591267648 0.184663709 miR - 24 2.935123408 0.004880222 3.008964137 0.031840324 miR - 24 - 2 * 8.262577106 0.009778614 7.379976617 0.021881848 miR - 25 3.301359495 0.009211953 3.953525313 0.147449509 miR - 26a 0.955412338 0.868020022 1.122090337 0.755335075 miR - 26b 0.622394369 0.187404783 1.383676479 0.39095235. . 26. . WO 2012 / 013821. PCT / EP2011 / 063233. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . miRNA fo|d change p va|ue fo|d change p va|ue miR - 26b * 1.57311448 0.16447827 2.513156903 0.030023219 miR - 27a 2.128180224 0.029237804 1.854173712 0.086001101 miR - 27a * 14.50243499 0.010592223 8.470060818 0.045703577 miR - 27b 0.564000917 0.210139343 0.73676401 0.494743354 miR - 27b * 2.019547735 0.19087909 3.221104938 0.089837184 miR - 28 2.53628581 0.011718545 2.18151906 0.021881848 miR - 28 * 3.334422074 0.010296625 2.616597308 0.093681498 miR - 292 - 3p 0.756824001 0.462734767 1.467777214 0.289229344 miR - 294 0.284616114 0.025036412 0.460831722 0.445352694 miR - 296 0.57961935 0.339739106 0.553266603 0.336484438 miR - 296 - 3p 2.793743218 0.141726173 2.739625394 0.156890504 miR - 297a * 1.971740006 0.113284896 2.010202832 0.12049269 miR - 298 4.078869679 0.101060762 2.662832771 0.209875402 miR - 29a 1.106416311 0.864949181 1.046986915 0.961527386 miR - 29a * 0.982755597 0.975686838 1.106716723 0.920800726 miR - 29b 0.532832996 0.338434293 0.645308267 0.613669566 miR - 29b * 1.128941383 0.404392937 1.119747668 0.689327143 miR - 29c * 0.63573551 0.350076141 1.275140009 0.709363957 miR - 300 * 0.70568922 0.428115117 0.875143602 0.846473322 miR - 301 4.171971098 0.025036412 4.175698588 0.037187565 miR - 301b 3.731903884 0.025648621 3.878303154 0.032975304 miR - 30a - 3p 1.181700893 0.568071703 1.51203164 0.209875402 miR - 30a - 5p 0.764071999 0.370256504 1.112925416 0.793409148 miR - 30b * 0.743174547 0.233382276 1.559178475 0.398452113 miR - 30C 1.186731174 0.38520049 1.733321867 0.127055907 miR - 30C - 2 * 0.288265326 0.370256504 0.680034832 0.779398143 miR - 30d 0.75400365 0.265997027 0.990977927 0.977738661 miR - 30e 1.046184279 0.801569724 1.685014195 0.17380784 miR - 30e - 3p 1.312239675 0.299729218 1.762942388 0.090516995 miR - 31 1.258277385 0.339739106 0.882067364 0.735171366 miR - 31 * 1.302160544 0.362179657 0.997946753 0.992428383 miR - 32 1.968680846 0.128099157 2.787876058 0.083290936 miR - 320 1.68260058 0.121654045 1.549664415 0.169906827 miR - 322 * 3.186523933 0.058839215 4.027983886 0.048681312 miR - 323 - 3p 1.385764477 0.311612691 1.126559487 0.719103365 miR - 324 - 3p 1.693398183 0.151319454 1.346138634 0.374315528 miR - 324 - 5p 1.386265489 0.370899476 1.367864504 0.427515762 miR - 326 1.339559268 0.412198934 1.048609239 0.690257512 miR - 328 0.401820455 0.121654045 0.341491126 0.101075499 miR - 329 0.392018347 0.01960028 0.392297259 0.021881848 miR - 330 0.376728552 0.047566241 0.410819253 0.086001101 miR - 330 - 5p 0.208501643 0.021084568 0.244828159 0.06894565 miR - 331 1.215237109 0.395284529 1.156358906 0.555544935 miR - 331 - 5p 1.329401064 0.200967878 1.097067146 0.433778552 miR - 335 0.34794996 0.091473239 0.60235664 0.363569096 miR - 335 * 0.492432367 0.081265395 1.127428997 0.726765601 miR - 337 - 3p 0.922626731 0.747038992 0.987637197 0.977738661 miR - 337 - 5p 1.135879266 0.550334698 0.975404531 0.942290692 miR - 338 - 3p 1.264343814 0.481069555 1.047223646 0.927148592 miR - 339 - 3p 1.512618669 0.105930341 3.051383536 0.021881848 miR - 339 - 5p 0.718037823 0.199777922 0.909743133 0.71427332 miR - 33a * 2.581623585 0.046809672 3.978300936 0.037187565 miR - 340 3.188345552 0.071604623 3.084818792 0.083302341 miR - 340 * 2.667250664 0.068172479 2.610031398 0.076261141 miR - 342 - 3p 3.997027494 0.017397038 3.753691047 0.021881848 miR - 342 - 5p 2.500670539 0.066726255 2.487495781 0.081726277 miR - 344 1.655242867 0.176101917 1.285483116 0.448692586 miR - 345 - 3p 0.92216192 0.82850515 1.135903869 0.76428247 miR - 345 - 5p 0.687386734 0.299729218 0.932411689 0.846473322. . 27. . WO 2012 / 013821. PCT / EP2011 / 063233. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . miRNA fo|d change p va|ue fo|d change p va|ue miR - 34b - 3p 10.55748467 0.001159773 5.124725257 0.083290936 miR - 34b - 5p 7.063390153 0.002195316 3.821921762 0.008284863 miR - 34c 5.707106215 0.004880222 2.629549816 0.048681312 miR - 34c * 3.72344702 0.004880222 3.304202056 0.044361147 miR - 350 2.207086231 0.029314715 2.065103962 0.081908469 miR - 361 0.552326147 0.065612423 0.585848584 0.12135725 miR - 362 - 3p 0.633463031 0.037408149 1.195985373 0.720252214 miR - 362 - 5p 2.221917366 0.091171643 2.71380723 0.045032645 miR - 365 0.824623509 0.595041808 0.783795889 0.608286912 miR - 369 - 3p 0.819879142 0.652767457 0.684251965 0.419175589 miR - 369 - 5p 0.661743335 0.336087302 0.524967159 0.204276192 miR - 370 1.793307426 O.172214176 1.49546994 O.321170272 miR - 374 - 5p 14.90076157 0.00269215 18.4683778 0.008284863 miR - 375 0.026637006 0.046666911 0.030708812 0.048681312 miR - 376a 1.329384861 0.529884042 1.274801167 0.664490289 miR - 376a * 1.488607762 0.329228454 1.745751338 0.36261197 miR - 376b 1.642789821 0.368672372 1.253600212 0.71364656 miR - 376b * 1.527510888 0.350076141 1.613538586 0.398452113 miR - 376C 4.800449482 0.025036412 4.883448374 0.030023219 miR - 379 2.591977294 0.029314715 2.166626535 0.045703577 miR - 380 - 5p 1.858433626 0.068257972 1.804782827 0.14130197 miR - 381 0.840433066 0.783714269 0.837869954 0.793409148 miR - 382 0.680076053 0.377542333 0.664518105 0.405733666 miR - 383 0.604287357 0.570538299 0.657994796 0.692629097 miR - 384 - 3p 0.830275623 0.477475762 0.749497028 0.514504677 miR - 384 - 5p 1.263544957 0.356435352 1.256898147 0.555544935 miR - 409 - 3p 1.668592979 0.086848647 1.411265241 0.187850527 miR - 409 - 5p 0.263755713 0.030591879 0.233114933 0.031840324 miR - 410 0.741091926 0.4093458 0.808024249 0.596983315 miR - 411 3.542896933 0.013065457 2.935804524 0.021881848 miR - 411 * 2.480316104 0.006051333 2.509954849 0.045032645 miR - 412 0.76903269 0.469533282 0.729580249 0.458576975 miR - 423 - 5p 0.487791913 0.273296662 0.742411259 0.647239401 miR - 424 3.428612823 0.023285286 2.594904442 0.048995445 miR - 425 1.385804901 0.19087909 2.243967185 0.044361147 miR - 431 2.883067265 0.051828341 2.914596654 0.13912127 miR - 433 0.393321988 0.151319454 0.360022629 0.14130197 miR - 434 - 3p 0.90344285 0.767783897 0.893649494 0.782556356 miR - 434 - 5p 1.613209246 0.310939846 1.394632488 0.489816324 miR - 448 0.422943062 0.121654045 0.248566155 0.049181724 miR - 449 102.6824215 0.004880222 56.61076425 0.088862403 miR - 449b 128.9933081 0.004880222 44.61289388 0.116681589 miR - 450a 1.381592985 0.183220355 0.830173285 0.585232362 miR - 465a - 3p 1.99424507 0.273296662 1.99424507 0.289229344 miR - 466d - 3p 1.585382229 0.233382276 1.585382229 0.249458962 miR - 467 * 1.723813659 0.036500299 1.922333409 0.037187565 miR - 467b 1.54226347 0.148331233 1.505981445 0.08226263 miR - 467c 5.252469016 0.003001541 3.688157233 0.101841409 miR - 467d 4.959036126 0.01960028 3.490504124 0.1249962 miR - 467e 1.14489331 0.545017463 0.964910193 0.91993227 miR - 470 * 0.461332125 0.271593853 0.821692068 0.76428247 miR - 483 * 41.75718578 O.154057991 16.19056621 0.274864415 miR - 484 2.600402741 0.004880222 2.25064809 0.02196098 miR - 485 - 3p 1.224395796 0.491579492 1.200872579 0.57670453 miR - 485 - 5p 0.758859203 0.456333899 0.721217957 0.552196956 miR - 487b 1.068581679 0.903647597 0.51057984 0.492132068 miR - 488 * 2.399873308 0.057413845 2.039168975 0.086350539 miR - 489 2.237001632 0.439867626 2.015723732 0.552196956 miR - 491 1.668119812 0.121654045 1.526443999 0.187741925. . 28. . WO 2012 / 013821. PCT / EP2011 / 063233. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . miRNA fo|d change p va|ue fo|d change p va|ue miR - 493 2.288713925 0.218610127 2.239356065 0.242136244 miR - 494 1.919773463 0.065556364 1.490057663 0.176394532 miR - 495 0.764449222 0.439496494 0.672112821 0.374327019 miR - 496 0.434944607 0.124402182 0.369536813 0.090087879 miR - 497 5.181492004 0.009211953 2.7617805 0.090087879 miR - 500 0.821677071 0.425002275 1.072299931 0.814600896 miR - 501 * 0.596201536 0.139840583 1.206867544 0.675993427 miR - 503 1.711918045 0.180312483 1.711918045 0.193963821 miR - 503 * 3.126537158 0.046809672 3.243329079 0.048681312 miR - 504 0.358906171 0.2919671 0.507132848 0.552196956 miR - 532 2.121351093 0.046666911 2.280616436 0.045032645 miR - 532 - 3p 1.782203809 0.01102795 1.607152405 0.03182938 miR - 541 2.942632062 0.077241102 2.491735463 0.1249962 miR - 542 - 3p 0.855281405 0.477475762 1.306195185 0.40382326 miR - 542 - 5p 0.950842963 0.902032977 1.424200536 0.254267886 miR - 543 0.524686562 0.087217891 0.446754499 0.076261141 miR - 544 0.345383264 0.088943386 0.350655233 0.14130197 miR - 547 2.541613068 0.08836386 2.217181941 0.125039073 miR - 551b 0.28349257 0.287355951 0.277024071 0.292826252 miR - 574 - 3p 2.973537623 0.007422321 2.515454473 0.045032645 miR - 582 - 3p 4.165620504 0.057413845 4.138268237 0.070133539 miR - 582 - 5p 1.399029044 0.456333899 1.17434746 0.755335075 miR - 592 2.289089699 0.271593853 1.778765192 0.433778552 miR - 598 0.426074317 0.068257972 0.408875563 0.088773549 miR - 652 0.636293739 0.194070228 0.700346562 0.29089308 miR - 665 1.700791643 0.19087909 1.035713632 0.955360333 miR - 666 0.473046844 0.116648667 0.407443158 0.08761121 miR - 667 0.711059691 0.336087302 0.642043519 0.258536706 miR - 668 0.290739651 0.178598651 0.246709498 0.153516058 miR - 669a 1.449460227 0.166039541 1.222400887 0.494586921 miR - 671 - 3p 1.374227314 0.143397391 1.305526804 0.209875402 miR - 672 8.983491367 0.001838729 4.031887344 0.076261141 miR - 673 2.492276551 0.020873863 2.043056703 0.060357995 miR - 673 - 3p 1.635569434 0.369116137 1.635569434 0.404595183 miR - 674 1.155102262 0.594497898 1.118446046 0.755335075 miR - 674 * 2.226094873 0.028402843 2.175479108 0.028237922 miR - 676 1.583016083 0.288734017 0.989037638 0.97786865 miR - 676 * 1.931133627 0.121914991 1.401418726 0.374327019 miR - 677 2.166066503 0.013845756 1.268218255 0.675993427 miR - 678 0.951977191 0.828543422 0.92431852 0.735171366 miR - 680 1.995818651 0.159229059 1.995818651 0.170193706 miR - 682 2.011180321 0.273296662 1.684415297 0.406256121 miR - 684 1.792610927 0.238613487 1.139238088 0.880698728 miR - 685 2.325010927 0.38520049 2.644261601 0.374315528 miR - 690 2.338722322 0.01960028 2.733449386 0.028768204 miR - 694 1.839427985 0.029314715 1.40766756 0.088210532 miR - 699 1.029833303 0.886038235 1.383595518 0.205791448 miR - 7 * 2.095520783 0.057413845 3.162943047 0.045032645 miR - 700 1.177692243 0.545017463 1.350393622 0.13464374 miR - 701 8.360447968 0.016106684 7.559666875 0.021881848 miR - 702 0.295973602 0.035503778 0.367094184 0.086001101 miR - 704 0.498610757 0.076092689 0.617381002 0.076261141 miR - 706 3.315589915 0.034057514 3.212761001 0.048681312 miR - 708 1.862467279 0.547038088 1.662053508 0.675993427 miR - 709 2.41065996 0.01960028 2.279881086 0.032975304 miR - 720 3.141664044 0.046255445 3.112153735 0.090516995 miR - 721 1.012018813 0.932335465 1.028011824 0.927148592 miR - 741 1.197128719 0.356435352 1.197128719 O.393791022 miR - 744 1.408439893 0.251822108 1.416693905 0.26072901. . 29. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . WO 2012 / 013821 PCT / EP2011 / 063233 miRNA fo|d change p va|ue fo|d change p va|ue miR - 744 * 1.729464216 0.299729218 2.368809057 0.070772723 miR - 760 1.477122606 0.091171643 1.350277872 0.082523815 miR - 764 - 5p 0.848747797 0.370256504 0.752519347 0.184272096 miR - 770 - 3p 0.679425174 0.299729218 0.524444615 0.123910683 miR - 770 - 5p 0.205624489 0.091783392 0.167023585 0.08455984 miR - 7b 0.698605261 0.429744436 0.582983448 0.412944332 miR - 802 0.484868745 0.377542333 0.683187703 0.674028334 miR - 804 1.832576274 0.43434326 2.249789457 0.22743239 miR - 805 7.454970171 0.01102795 8.344999686 0.021881848 miR - 872 1.34031196 0.389235666 2.617246084 0.077926571 miR - 872 * 1.653821653 0.143397391 3.620843307 0.008284863 miR - 873 0.479110688 0.298230697 0.964124373 0.977738661 miR - 875 - 5p 0.50208087 0.120638185 0.847081339 0.689327143 miR - 877 * 0.653592007 0.123495218 0.70658629 0.209875402 miR - 878 - 3p 1.092119012 0.464148893 0.763159963 0.65946088 miR - 879 1.117983007 0.868020022 1.645889118 0.358211754 miR - 879 * 2.832452305 0.063455872 2.752840607 0.032975304 miR - 881 * 1.379222746 0.464148893 1.379222746 0.520838834 miR - 9 1.103277147 0.878261768 0.925655215 0.927148592 miR - 9 * 1.869502085 0.448244867 2.642650853 0.31397158 miR - 92 2.935771459 0.063681353 5.773853137 0.070020922 miR - 93 30.58766513 0.002195316 9.491046446 0.12573963 miR - 93 * 7.585371012 0.001838729 5.86831438 0.083302341 miR - 96 0.010674683 0.068893257 0.092353946 0.209875402 miR - 99a 1.974761714 0.34280185 1.537660844 0.552196956 miR - 99b 0.573127422 0.028147949 0.69967891 0.14130197 miR - 99b * 2.242795888 0.019861482 2.247101168 0.044361147 Tab|e 2. Differentia| miRNA expression in human tumors. tumour VS. norma| retina. . . . . . . . . . . . . . . . . . . . . . . . . . . miRNA fo|d change p va|ue hsa - |et - 7a 0.35537902 0.00013862 hSa - |et - 7b 0.09604549 7.16E - 06 hSa - |et - 7c 0.08579614 7.16E - 06 hSa - |et - 7d 0.2603711 0.00013862 hsa - |et - 7e 1.07286876 O.77502568 hsa - |et - 7f 0.34865756 0.00043067 hsa - |et - 7g 0.25157949 7.16E - 06 hsa - |et - 7i 0.31234196 4.01E - 05 hSa - mir - 1 0.05903321 0.00049403 hsa - mir - 100 0.08595542 7.16E - 06 hsa - mir - 101 0.34705063 0.00033484 hsa - mir - 103 2.72037506 7.16E - 06 hSa - miR - 105 1.57465508 0.09943833 hsa - mir - 106a 22.4668082 7.16E - 06 hsa - mir - 106b 10.6402635 7.16E - 06 hsa - mir - 10a 2.19201791 0.04611805 hsa - mir - 10b 1.34390722 0.74156615 hsa - mir - 124a 0.0900642 0.00043067 hSa - mir - 125a 0.52319617 0.00226454 hsa - mir - 125b 0.07878721 7.16E - 06 hsa - miR - 126 0.45730233 0.24270864 hSa - mir - 126 * 0.62578168 0.25602782 hsa - mir - 127 0.0342777 7.16E - 06. . . 30. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . WO 2012 / 013821 PCT / EP2011 / 063233 miRNA fo|d change p va|ue hsa - mir - 128a O.78245662 0.13861277 hsa - mir - 128b 0.32953805 0.00043067 hsa - mir - 129 O.28183933 7.16E - 06 hsa - mir - 130a 2.25433284 0.01339514 hsa - mir - 130b 21.4342907 7.16E - 06 hsa - mir - 132 1.49485219 0.0054634 hsa - mir - 133a 0.0436029 0.00018537 hsa - mir - 133b 0.06463161 0.00033484 hsa - mir - 134 0.04372136 7.16E - 06 hsa - mir - 135a O.68609293 0.32682787 hsa - mir - 135b 2.46777872 0.01539956 hsa - mir - 136 0.20587978 4.14E - 05 hsa - mir - 137 O.11902455 0.03203347 hsa - mir - 139 0.41085904 0.0013856 hsa - mir - 140 0.44076828 0.00897368 hsa - mir - 142 - 3p 1.00447986 0.85372115 hsa - mir - 142 - 5p 1.1893089 0.48954435 hsa - mir - 143 O.41216203 0.00025116 hsa - mir - 145 1.21216392 0.26976018 hsa - mir - 146a 0.68463308 0.19350179 hsa - miR - 146b 0.49382848 0.05480526 hsa - mir - 147 1.02106039 O.72621669 hsa - mir - 148a O.43564789 0.00152628 hsa - mir - 148b 0.80433376 0.30889578 hsa - mir - 149 1.01129007 0.90770942 hsa - mir - 15O O.50410072 0.0227267 hsa - mir - 151 1.07359588 0.46559024 hsa - mir - 152 O.2517561 7.16E - 06 hsa - mir - 153 O.39547506 0.0117662 hsa - mir - 155 2.13489084 0.01749556 hsa - mir - 15a 2.06363552 0.00900422 hsa - mir - 15b 26.1777272 7.16E - 06 hsa - mir - 16 7.00699074 7.16E - 06 hsa - mir - 17 - 3p 2.9472995 0.00025116 hsa - mir - 17 - 5p 26.3119159 0.00043067 hsa - mir - 181a O.41250441 0.0018715 hsa - mir - 181b O.4559957 0.00418778 hsa - mir - 181c O.38846465 0.00018537 hsa - mir - 181d 0.70318804 0.12703441 hsa - mir - 182 O.35232871 0.00043067 hsa - mir - 182 * O.42557789 0.01749556 hsa - mir - 183 0.5743967 0.02859318 hsa - mir - 184 0.06398151 7.16E - 06 hsa - miR - 185 1.54155538 0.12703441 hsa - mir - 186 1.85438899 0.00124058 hsa - mir - 187 0.46481307 O.39367912 hsa - mir - 188 O.88806239 0.72621669 hsa - mir - 189 0.16893503 0.00030233 hsa - mir - 18a 79.0815882 7.16E - 06 hsa - mir - 18a * 63.9114703 7.16E - 06 hsa - mir - 19O 1.64013997 0.2889012 hsa - mir - 191 1.10477886 0.26976018 hsa - mir - 192 O.14622399 7.16E - 06 hsa - mir - 193a 1.16789826 0.67465852 hsa - mir - 193b 4.2090245 0.00013862 hsa - mir - 194 O.20907205 7.16E - 06 hsa - mir - 195 2.85739458 0.00018537 hsa - mir - 196a 16.7342353 0.00043067 hsa - mir - 196b 17.7581272 0.00043067. . . . 31. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . WO 2012 / 013821 PCT / EP2011 / 063233 miRNA fo|d change p va|ue hsa - mir - 197 3.3116927 7.16E - 06 hsa - mir - 199a * 0.55000083 0.10843751 hsa - mir - 19a 6.88751333 7.16E - 06 hsa - mir - 19b 4.49373357 1.30E - 05 hsa - mir - 200b 0.42791773 0.00378473 hsa - mir - 200c 1.41579868 0.01749556 hsa - mir - 202 1.1245744 0.26368061 hsa - mir - 203 O.83558823 0.48954435 hsa - mir - 204 0.03706516 7.16E - 06 hsa - mir - 205 O.53675893 0.07581168 hsa - mir - 206 0.95807252 0.77502568 hsa - mir - 20a 26.4811479 7.16E - 06 hsa - mir - 20b 14.1612372 7.16E - 06 hsa - mir - 21 0.57656504 0.01339514 hsa - mir - 210 0.96285721 0.99060345 hsa - mir - 211 0.02482795 0.00043067 hsa - mir - 213 O.48361999 0.24766578 hsa - mir - 214 1.38943797 O.12703441 hsa - mir - 216 2.32107449 0.00939182 hsa - mir - 217 7.81322416 1.30E - 05 hsa - mir - 218 O.25179093 0.00762549 hsa - mir - 219 0.94631518 O.960105 hsa - mir - 22 0.05253163 7.16E - 06 hsa - mir - 221 1.40947664 0.5272094 hsa - mir - 222 1.09339696 0.67465852 hsa - mir - 223 O.89534602 0.85372115 hsa - mir - 224 291.864825 7.16E - 06 hsa - mir - 23b O.42004824 2.44E - 05 hsa - mir - 24 O.63896374 0.04906702 hsa - mir - 25 15.6401857 7.16E - 06 hsa - mir - 26a O.59553671 0.04427405 hsa - mir - 26b O.5583957 0.03203347 hsa - mir - 27a 0.3573996 0.00025116 hsa - mir - 27b O.36225236 7.16E - 06 hsa - mir - 28 1.03190904 0.64778272 hsa - mir - 296 2.13514657 0.00013862 hsa - mir - 29a 0.0421722 7.16E - 06 hsa - mir - 29b 0.0482461 000021017 hsa - mir - 29c 0.02886594 7.16E - 06 hsa - mir - 301 7.42502783 0.00043067 hsa - mir - 302a O.83938937 0.56829947 hsa - mir - 302b 0.67342364 0.52689892 hsa - mir - 302c 1.19328061 0.77502568 hsa - mir - 30a - 3p O.14800778 7.16E - 06 hsa - mir - 30a - 5p O.53136762 0.00063136 hsa - mir - 30b 0.54588527 0.01339514 hsa - mir - 30c O.55939359 0.00391308 hsa - mir - 30d 0.7681248 0.53670222 hsa - mir - 30e - 3p 0.21060566 4.01E - 05 hsa - mir - 31 0.02101799 0.00043067 hsa - mir - 32 1.76548942 0.04427405 hsa - mir - 320 1.12000353 0.3483077 hsa - mir - 323 O.33369345 0.00141352 hsa - mir - 324 - 3p 1.26345004 0.25054001 hsa - mir - 324 - 5p 1.93278119 0.00226454 hsa - mir - 328 O.33475394 0.00013862 hsa - mir - 329 0.05237916 0.0007761 hsa - mir - 33 0.48968232 0.091318 hsa - mir - 33O 0.09526962 0.00043067. . . . 32. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . WO 2012 / 013821 PCT / EP2011 / 063233 miRNA fo|d change p va|ue hsa - mir - 331 1.20513488 006785334 hsa - mir - 335 0.31105792 6.49E - 05 hsa - mir - 337 O.20862313 000900422 hsa - mir - 338 O.95192321 0.72621669 hsa - mir - 339 0.97027964 0.99060345 hsa - mir - 34O 4.3996595 401E - 05 hsa - mir - 342 1.20499242 0.26976018 hsa - mir - 345 2.23359741 000063136 hsa - mir - 34a 3.29325121 000251841 hsa - mir - 34b 2.18090789 000404264 hsa - mir - 34c 11.480094 0.00043067 hsa - mir - 361 1.64485503 000018537 hsa - mir - 362 4.66675665 9.72E - 05 hsa - mir - 363 0.76690276 0.26976018 hsa - mir - 365 3.18513195 0.00043067 hsa - mir - 367 O.78848663 0.70717062 hsa - mir - 368 O.2349716 000010121 hsa - mir - 369 - 3p O02751693 000091092 hsa - mir - 369 - 5p O08361946 000251841 hsa - mir - 370 0.07476827 0.00060692 hsa - mir - 371 O.48418781 O.10843751 hsa - mir - 372 O.54306705 O04415163 hsa - mir - 373 O.95097536 0.62116166 hsa - mir - 374 1.99163251 0.08189477 hsa - mir - 375 1.25035362 0.85372115 hsa - mir - 376a O07683527 000049403 hsa - miR - 376a * O09681493 9.39E - 06 hsa - mir - 378 O.12962734 7.16E - 06 hsa - mir - 379 O03956945 000025116 hsa - miR - 380 - 5p 0.03800462 0.00069548 hsa - mir - 381 O.46185069 O0254578 hsa - mir - 382 O0307304 000017972 hsa - mir - 383 0.0283853 0.00049403 hsa - mir - 409 - 5p O.3510641 000048429 hsa - mir - 41O O05228181 000124058 hsa - mir - 411 O0505212 00022499 hsa - mir - 422a O.19101909 9.72E - 05 hsa - mir - 422b O.12338888 000055578 hsa - mir - 423 1.28423439 0.00939182 hsa - mir - 424 O.37428883 O02624396 hsa - mir - 425 1.28014247 00244766 hsa - miR - 425 - 5p 1.62536378 0.03203347 hsa - mir - 429 0.3929063 000994593 hsa - mir - 432 O0528755 000332382 hsa - mir - 432 * O.27657592 000163922 hsa - mir - 433 003069235 000031742 hsa - mir - 449 155.434676 000043067 hsa - mir - 449b 16.6971009 0.00043067 hsa - mir - 451 O.46332132 O01339514 hsa - mir - 452 * 500864717 000043067 hsa - mir - 455 O.7951811 0.62116166 hsa - miR - 484 1.17789333 0.52511306 hsa - mir - 485 - 3p O.11089838 000063136 hsa - mir - 486 5.9867152 7.16E - 06 hsa - mir - 487a 0.34346089 1.49E - 05 hsa - mir - 487b O03597225 000074741 hsa - miR - 488 0.20122425 9.72E - 05 hsa - mir - 489 0.31905186 0.00900422 hsa - mir - 491 0.36527896 000081334. . . . 33. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . WO 2012 / 013821 PCT / EP2011 / 063233 miRNA fo|d change p va|ue hsa - mir - 493 - 3p O.68599194 000259778 hsa - mir - 495 0.03849728 000076348 hsa - mir - 496 O.3300278 000479033 hsa - mir - 497 O.2185559 000074164 hsa - mir - 500 3.25977843 001446879 hsa - mir - 501 4.79990937 000404264 hsa - mir - 502 4.99722754 000378473 hsa - miR - 504 O.48939463 001584247 hsa - mir - 511 1.99855529 O03799159 hsa - mir - 516 - 3p 2.69457618 00007761 hsa - mir - 517c 0.69861325 0.25602782 hsa - mir - 518b O.68684019 O.24796386 hsa - mir - 520b 1.62964764 002510968 hsa - mir - 520c 0.70751266 0.32020428 hsa - mir - 520d 1.14690339 0.93441565 hsa - mir - 520f 1.11158693 0.90770942 hsa - mir - 520g 1.3021177 0.90770942 hsa - mir - 524 1.43984302 O.1241732 hsa - mir - 526b * 1.0973129 1 hsa - miR - 532 3.49359963 000098366 hsa - mir - 539 O05218903 00007761 hsa - mir - 542 - 3p O.14402793 000124243 hsa - mir - 544 2.62052266 002211232 hsa - miR - 545 1.01146185 0.90770942 hsa - miR - 548a 205655775 002510968 hsa - miR - 548c 1.45298408 0.49035982 hsa - mir - 548d 67.9436778 000043067 hsa - mir - 55O 7.76782145 7.16E - 06 hsa - mir - 551b 1.89296142 007482871 hsa - miR - 556 1.40849181 0.10164507 hsa - mir - 563 1.83609752 O.22335188 hsa - mir - 564 O.80404032 0.69033352 hsa - mir - 565 1.86022235 0.04427405 hsa - mir - 572 1.57248444 0.11788226 hsa - mir - 574 1.7388258 00400753 hsa - miR - 576 3.46042567 000939182 hsa - miR - 579 1.45550865 O.17876651 hsa - mir - 58O 1.67404523 007581168 hsa - mir - 586 3.5635258 000416508 hsa - miR - 589 2.73919005 O02246324 hsa - miR - 591 1.78203829 0.32614379 hsa - miR - 592 3.68492668 000391308 hsa - miR - 594 5.95325565 0.0018715 hsa - miR - 597 107407362 0.93441565 hsa - mir - 601 1.56904541 0.20907235 hsa - mir - 604 0.89158812 O.85372115 hsa - miR - 606 O.93037864 0.83163543 hsa - mir - 610 1.67142973 004906702 hsa - mir - 616 1.13999295 O.46559024 hsa - miR - 617 O.99644562 1 hsa - miR - 618 O.55607267 0.11788226 hsa - mir - 624 0.71607099 0.38454635 hsa - mir - 627 1.17089243 0.85372115 hsa - miR - 628 1.76076528 006916151 hsa - miR - 629 13.7301513 7.16E - 06 hsa - mir - 63O O.91056169 0.64778272 hsa - mir - 632 2.19061098 0.02859318 hsa - miR - 638 1.36058072 0.43080058 hsa - mir - 639 1.28944024 O.7278872. . . . 34. . . . . . . . . . . . . . . . . . . . . . . . WO 2012 / 013821 PCT / EP2011 / 063233 miRNA fo|d change p va|ue hsa - miR - 641 1.17976993 0.77502568 hsa - miR - 642 0.67712899 0.85372115 hsa - mir - 643 1.35673645 O.15056971 hsa - miR - 645 O.65285887 00400753 hsa - mir - 650 1.3372344 0.4175414 hsa - mir - 651 2.83286228 000569964 hsa - miR - 653 O.33088794 000250862 hsa - mir - 655 O06240409 000200424 hsa - mir - 656 0.13595654 000017353 hsa - mir - 66O 1.75285267 00610666 hsa - mir - 7 42.6616607 7.16E - 06 hsa - mir - 9 O.26396093 6.49E - 05 hsa - mir - 9 * O.19311894 2.44E - 05 hsa - mir - 92 6.40573466 7.16E - 06 hsa - mir - 93 23.3811787 7.16E - 06 hsa - mir - 95 2.18070927 003239561 hsa - mir - 96 O.15148064 1.30E - 05 hsa - mir - 98 0.350188 O03239561 hsa - mir - 99a O09033381 7.16E - 06 hsa - mir - 99b 1.46567717 0.00762549. . . . 35. . WO 2012 / 013821. Tab|e 3 List of miRNAs that are up - regu|ated both in mouse and human tumours. Co|umn 1 : miRNAs ; co|umn 2 : Murine tumour vs. norma| retina ; co|umn 3 : Human tumour vs. norma| retina ; co|umn 4 : Mouse Va|idated targets according to http : iimirecords. bioiead. org / ; . co|umn 5 : Human Va|idated targets. PCT / EP2011 / 063233. . . according to http : / / mirecords. bio|ead. org / . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . miR— 128.9933081 16.69710093 —. 449b. miR— 102.6824215 155.4346758 E2F5. 449. iiiiii - 72.27794902 79.08158818. 18a. miR - 51.88732466 22.46680818 MYLlP , ARlD4B , LOC100048439 VEGFA , RB1 , RUNX1 , APP. 106a. miR - 47.58305778 26.31191595 RB2 ( p130 ) NCOA3 , VEGFA , RUNX1 , CCND1 miR - 45.10422985 14.16123719 MYL|P , ARlD4B , LOC100048439 VEGFA. 20b. miR - 36.49125415 26.4811479 ZBTB7A , STAT3 VEGFA , E2F1 , RUNX1 , CCND1 2.0a. miR - 30.58766513 23.3811787 STAT3 E2F1 , VEGFA , CDKN1A ( p21Cip1 ) 93. miR - 10.94909897 4.493733566 MYLlP , LOC100048439. 3.91 ; : . miR - 9.927933234 6.887513332 PTEN. 19a. miR— 7.494097062 1.854388991. 186. miR - 7.461352046 63.91147033. 18a * . miR— 7.063390153 2.180907894. 34b. miR— 7.05075498 2.947299501. 17 * . miR - 6.475493206 10.64026349 E2F1 , VEGFA , CDKN1A ( p21Cip1 ) , lTCH 106b. miR— 5.933582476 2.134890842 SFP|1 , MYB , RHEB , BAT5 , JAR|D2 , TRP53lNP1 , AGTR1 , BACH1 ( FANCJ ) , LDOC1 , MATR3 , 155 |KBKE , FADD , R|PK1 , MAF , A|CDA , SOCS1 TM6SF1 , RHOA , ETS1 , ME|S1 miR— 5.707106215 11.48009405. 34c. miR - 5.453081609 26.17772719 BCL2 , CCNE1. 15b. miR— 4.171971098 7.425027828. 301. miR— 3.362819079 2.85739458. 195. iiiiR - 3.301359495 15.64018573. N. miR— 3.03333113 7.00699074 CCND1. 16. miR - 2.935771459 6.405734661 MYLlP , LOC100048439. miR - 2.121351093 3.493599628. 532. miR— 1.714212739 2.254332844 TAC1 , CSF1 , MAFB , MEOX2 , HOXA5 130a. . miRNAS in red be|ong to the miR - 17 - 92 or the two para|ogue c|usters ; targets found more than once are high|ighted in bo|d. 36. . 10. 15. 20. 25. 30. WO 2012 / 013821 PCT / EP2011 / 063233. Materia|s and Methods. Mice A|| anima| experiments were perf0rmed in accordance with the guide|ines of the University of Leuven Anima| Care and Use ethica| Committee. BrdU ( 100 ug / g of body weight ) was injected intraperitonea||y. 1hr prior to sacrifice. lmmunohistochemistry. Eyes were fixed overnight in 4% paraf0rma|dehyde / PBS , and paraffin embedded. 5um sections were immunostained with the fo||owing antibodies : GFP ( Santa Cruz Biotechno|ogy , 1 / 100 ) ; BrdU ( BD Pharmingen ) ; Ki - 67 ( DAKO cytomation ) ; c|eaved Caspase - 3 ( Ce|| Signa|ing ) ; GFP ( Santa Cruz Bi0techn0|0gy ) ; Chx10 ( Exa|pha Bio|ogica|s ) ; syntaxin ( Sigma ) ; ca|bindin ( Abcam ) ; Ca|retinin ( Mi||ip0re ) . AP staining. Dissected retinae were fixed for 1h in 4% paraforma|dehyde / PBS on ice , heated t0 65°C for 30min and embedded in 4% agarose / PBS. 40um sections were rinsed once in AP detection buffer ( 100mM Tris pH9.5 , 50mM MgC|2 , 100 mM NaC| ) before deve|oping in Nitro b|ue tetrazo|ium ch|oride / 5 - Bromo - 4 - ch|oro - 3 - ind0|y| phosphate ( NBT / BC|P Ready - to - use tab|ets , R0che ) f0r 4h. Recombination ana|ysis. DNA was iso|ated from dissected retinae and is0|ated tumours using DNeasy B|ood&Tissue Kit ( Qiagen ) . Dicer1 rec0mbination was ana|yzed by PCR using the fo||owing primers : a 5— ATTGTTACCAGCGCTTAGAATTCC ; c 5 ' - TCGGAAT AGGAACTTCGTTTAAAC and the reverse b primer 5 - GGGAGGTGTACGTCTA CAATT. P53 recombination was ana|yzed by PCR using the fo||owing primers : d 5 ' - CACAAAAACAGGTTAAACCCAG and the reverse primers f 5 - AGCACATAGGAGGCAGAGAC and e 5 ' - GAAGACAGAAAAGGGGAGGG. PCR conditions were as fo||ow : 1x precyc|e at 94°C for 3min and 30cyc|es of 94°C , 30sec ; 60°C , 30sec ; 72°C , 45sec. Retinob|astoma tumour samp|es and RNA iso|ation. |mmediate|y f0||owing enuc|eation , dissected retinae or tum0ur samp|es were removed from the mouse eyes under the binocu|ar using forceps. The specimens were p|aced on ice and immediate|y processed for RNA or DNA iso|ation. Before tumour samp|es were co||ected from human retin0b|astoma samp|es , seria| cryosections where obtained from a|| tumours. The first and |ast cryosection 0f each series were H&E stained for tumour ce|| content verification. 3 - 5mm3 samp|es were p|aced on ice and immediate|y processed for RNA and DNA iso|ation. Tota| RNA and genomic DNA were iso|ated using the miRNeasy kit ( Qiagen ) and the Q|Amp mini kit ( Qiagen ) , respective|y , according. to manufacturers instructions. Written informed consent was obtained from patients and / or their. 37. 10. 15. 20. 25. 30. WO 2012 / 013821 PCT / EP2011 / 063233. parents. A|| procedures have been approved by the institutiona| review board of the Chi|drens. University Hospita| of Essen. microRNA Expression ana|yses. For human samp|es , miRNA expression profi|ing was performed as described previous|y ( 24 ) . For murine samp|es , 60 ng of tota| RNA was reverse transcribed using the murine stem - |oop megap|ex poo| A and B fo||owed by |imited cyc|e pre - amp|ification ( App|ied Biosystems ) . Expression of 430 human and 509 murine miRNAs was pr0fi|ed using Taqman miRNA assays on a 7900HT detection system ( App|ied Biosystems ) . Data were norma|ized using the g|oba| mean ( 25 ) . miRNA expression data are avai|ab|e as RDML - fi|es up0n request ( 26 ) . Differentia||y expressed miRNAs were identified using the MannWhitney test fo||owed by mu|tip|e testing correction according to the Benjamini - Hochberg a|gorithm. Hierarchica| c|ustering was performed using method Ward and distance Manhattan. A|| statistica|. ana|yses were performed using R Bioconductor software. Array CGH. Samp|es were profi|ed on a cust0m designed 44K / 60K array ( Agi|ent Techno|ogies ) enriched f0r miRNA and T - UCR regions and regions around cancer gene census genes. Uti|izing random prime |abe||ing ( BioPrime ArrayCGH Genomic Labe|ing System , |nvitrogen ) , 150 ng of test and contro| DNA ( DNA from an EBV ce|| |ine if ce|| |ines were tested 0r ma|e c0ntro| DNA , Promega if tum0ur samp|es were tested ) was |abe|ed with Cy3 and Cy5 dyes ( GE hea|thcare ) . S|ides were scanned using an Agi|ent scanner ( Agi|ent Techno|ogies ) an in - house deve|oped visua|isati0n software program arrayCGHbase. ( htth / medgen. ugent. be / arrayCGHbase ) ( 27 ) . Array CGH profi|es were eva|uated by using the circu|ary. . binary segmentation ( CBS ) a|gorithm. Ce|| cu|ture and |nhibition of miRNAs. Retinob|astoma ce|| |ines Weri and Y79 were authenticated by DNA fingerprinting ( DMSZ , Braunschweig , Germany ) . Ce||s were cu|tured in suspension in Du|becco ' s Modified Eag|es ' s Medium ( DMEM ) ( |nvitr0gen ) , containing 15% FCS , Penici||in / Strept0mycin , 4mM L - G|utamin , 50uM 8 - Mercaptoethano| and 0.1% |nsu|in ( a|| from |nvitrogen ) . 1x104 Weri and Y79 ce||s / we|| were seeded on 24 - we|| p|ates and transfected with specific antagomirs or scramb|ed Cy3 - |abe||ed contro| o|igos ( a|| from Ambion ) at a fina| concentration of 100nM using NeoFx transfection agent ( Ambion ) according to the manufacturers recommendations. Further , antisense inhibitors were designed against a|| members of the miR - 17 / 92 c|uster using the |ocked nuc|eic acid ( LNA ) techno|ogy. The inhibitors were. synthesized as fu||y phosph0rothio|ated DNA / LNA mixmers and purified by preparative HPLC before. 38. WO 2012 / 013821 PCT / EP2011 / 063233. use. The number and position of LNA nuc|eotides was chosen in each case in order to maximize affinity. and se|ectivity towards the specific miRNA target. 3 - ( 4 , 5 - Dimethy|thiaz0| - 2 - y| ) - 2 , 5 - dipheny|tetraz0|ium bromide ( MTI ' ) ce|| pro|iferation assay M ' |T assays were performed as previous|y described ( 28 ) . Brief|y , after the addition of 20O uL MTT so|ution ( 6 mg / mL in PBS , R0che , Germany ) , ce||s were incubated f0r 1h and then so|ubi|ized by the addition 0f 1 mL stop so|ution ( 10% SDS , 5% acetic acid in dimethy| su|foxide ) . Absorbance at 570 nm was measured. using a G|oMax® - Mu|ti Microp|ate Mu|tim0de Reader ( Promega ) . 39. 10. 15. 20. 25. 30. 35. WO 2012l013821 PCT / EP2011 / 063233. References. 1. 10. 11. 12. 13. 14. 15. 16. Croce , C. M. , Causes and consequences of microRNA dysregu|ation in cancer. Nat Rev Genet 10 ( 10 ) , 704 - 714 ( 2009 ) . Karube , Y. et al. , Reduced expressi0n of Dicer ass0ciated with po0r prognosis in |ung cancer patients. Cancer $ci 96 ( 2 ) , 111 - 115 ( 2005 ) . Kumar , M. S. , Lu , J. , Mercer , K. L. , Go|ub , T. R. , & Jacks , T. , |mpaired microRNA processing enhances ce||u|ar transformation and tumourigenesis. Nat Genet 39 ( 5 ) , 673 - 677 ( 2007 ) . Me|o , S. A. et ql. , A TARBP2 mutation in human cancer impairs microRNA processing and D|CER1 function. Not Genet 41 ( 3 ) , 365 - 370 ( 2009 ) . Pampa|akis , G. , Diamandis , E. P. , Katsar0s , D. , & Sotiropou|ou , G. , Down - regu|ation of dicer expression in ovarian cancer tissues. Clin Biochem ( 2009 ) . Hi|| , D. A. et ol. , D|CER1 mutations in fami|ia| p|europu|monary b|astoma. Science 325 ( 5943 ) , 965 ( 2009 ) . Kumar , M. S. et ol. , Dicer1functi0ns as a hap|0insufficient tumour suppress0r. Genes Dev ( 2009 ) . Lambertz , L et al. , Monoa||e|ic but not bia||e|ic |0ss 0f Dicer1 promotes tum0urigenesis in viv0. Cell Death Differ 17 ( 4 ) , 633 - 641. Arrate , M. P. et ol. , MicroRNA Biogenesis |s Required for Myc - |nduced B - Ce|| Lymphoma Deve|opment and Surviva|. Concer Res. Zhang , J. , Schweers , B. , & Dyer , M. A. , The first kn0ckout m0use mode| 0f retinob|astoma. Cell Cycle 3 ( 7 ) , 952 - 959 ( 2004 ) . Zhang , J. et al. , Rb regu|ates pro|iferation and r0d photoreceptor deve|0pment in the m0use retina. Nat Genet 36 ( 4 ) , 351 - 360 ( 2004 ) . Laurie , N. A. et ol. , |nactivation of the p53 pathway in retinob|astoma. Noture 444 ( 7115 ) , 61 - 66 ( 2006 ) . Donovan , S. L. , Schweers , B. , Martins , R. , Johnson , D. , 8 Dyer , M. A. , Compensation by tumour suppressor genes during retina| deve|opment in mice and humans. BlVlC Biol 4 , 14 ( 2006 ) . R0wan , S. & Cepk0 , C. L. , Genetic ana|ysis of the h0me0d0main transcription fact0r Chx10 in the retina using a nove| mu|tifunctiona| BAC transgenic mouse reporter. Dev Biol 271 ( 2 ) , 388 - 402 ( 2004 ) . Donovan , S. L. & Dyer , M. A. , Deve|0pmenta| defects in Rb - deficient retinae. Vision Res 44 ( 28 ) , 3323 - 3333 ( 2004 ) . Damiani , D. et ol. , Dicer inactivation |eads to progressive functiona| and structuradegeneration of the mouse retina. J Neurosci 28 ( 19 ) , 4878 - 4887 ( 2008 ) . 40. 10. 15. 20. 25. 30. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. WO 2012l013821 PCT / EP2011 / 063233. O|ive , V. , Jiang , |. , 8 He , L. , mir - 17 - 92 , a c|uster of miRNAs in the midst of the cancer network. lntJ Biochem Cell Biol. van Haaften , G. 8 Agami , R. , Tumourigenicity of the miR - 17 - 92 c|uster disti||ed. Genes Dev 24 ( 1 ) , 1 - 4. Shie|ds , CL 8 Shie|ds , J. A. , Basic understanding 0f current c|assificati0n and management 0f retinob|astoma. Curr Opin Ophtha|mo| 17 ( 3 ) , 228 - 234 ( 2006 ) . Aguda , B. D. , Kim , Y. , Piper - Hunter , M. G. , Friedman , A. , 8 Marsh , C. B. , MicroRNA regu|ation of a cancer network : consequences of the feedback |oops invo|ving miR - 17 - 92 , E2F , and Myc. Proc Notl Acad $ci U 5 A 105 ( 50 ) , 19678 - 19683 ( 2008 ) . Yan , H. L. et ol. , Repression of the miR - 17 - 92 c|uster by p53 has an important function in hypoxia - induced apoptosis. EMBOJ 28 ( 18 ) , 2719 - 2732 ( 2009 ) . Marine , J. C. , Journa| c|ub. A cancer geneticist |ooks at the |ink between sma|| RNA mo|ecu|es and cancer. thure 464 ( 7293 ) , 1249. Ma , L. et al. , Therapeutic si|encing 0f miR - 10b inhibits metastasis in a mouse mammary tumour mode|. Not Biotechnol 28 ( 4 ) , 341 - 347. Mestdagh , P. et ol. , High - throughput stem - |oop RT - qPCR miRNA expression profi|ing using minute amounts of input RNA. Nucleic Acids Res 36 ( 21 ) , e143 ( 2008 ) . Mestdagh , P. et dl. , A nove| and universa| method for microRNA RT - qPCR data norma|ization. Genome Biol 10 ( 6 ) , R64 ( 2009 ) . Lefever , S. et al. , RDML : structured |anguage and reporting guide|ines f0r rea| - time quantitative PCR data. Nucleic Acids Res 37 ( 7 ) , 2065 - 2069 ( 2009 ) . Menten , B. et dl. , arrayCGHbase : an ana|ysis p|atform for comparative genomic hybridization micr0arrays. BMC Bioinformatics 6 , 124 ( 2005 ) . Mosmann , T. , Rapid co|orimetric assay for ce||u|ar growth and surviva| : app|ication to pro|iferation and cytotoxicity assays. J lmmunol Methods 65 ( 1 - 2 ) , 55 - 63 ( 1983 ) . Levine , A. J. , p53 , the ce||u|ar gatekeeper for growth and divisi0n. Cell 88 ( 3 ) , 323 - 331 ( 1997 ) . Kae|in WG Jr. , The concept of synthetic |etha|ity in the context of anticancer therapy. Not Rev Cdncer , 5 ( 9 ) : 689 - 98 ( 2005 ) . Farmer H , et dl. , Targeting the DNA repair defect in BRCA mutant ce||s as a therapeutic strategy. thure 434 : 917 - 921 ( 2005 ) . Fong PC , et dl. , |nhibition of p0|y ( ADP - ribose ) po|ymerase in tumors from BRCA mutation carriers. N EnglJ Med ; 361 : 123 - 134 ( 2009 ) . Nevins JR. , The Rb / E2F pathway and cancer. Hum Mol Genet ; 10 ( 7 ) : 699 - 703 ( 2001 ) . 41. 10. 34. 35. 36. 37. 38. 39. WO 2012l013821 PCT / EP2011 / 063233. Burkhart DL , et ol. , Ce||u|ar mechanisms of tumour suppression by the retinob|astoma gene. Not Rev Concer ; 8 ( 9 ) : 671 - 82 ( 2008 ) . Barte| B , MicroRNAs directing siRNA biogenesis. th $truct Mol Biol ; 12 ( 7 ) : 569 - 71 ( 2005 ) . Ryan BM , et al. , Genetic variati0n in microRNA networks : the imp|ications for cancer research. th Rev Cancer ; 10 ( 6 ) : 389 - 402 ( 2010 ) . Ventura A , et al. , Targeted De|etion Revea|s Essentia| and Over|apping Functions of the miR - 17 - 92 Fami|y of miRNA C|usters. Cell 132 , 875—886 , ( 2008 ) . Tanzer A , et dl. , Mo|ecu|ar evo|uti0n of a microRNA c|uster. J Mol Biol ; 339 : 327—35 ( 2004 ) . Kriitzfe|dt J , et ol. , Si|encing of microRNAs in vivo with ' antagomirs ' . Noture 1 ; 438 ( 7068 ) : 685 - 9 ( 2005 ) . 42. 10. 15. 20. 25. WO 2012l013821 PCT / EP2011 / 063233. C|aims. 1. 10. 11. 12. 13. 14. 15. A method of inducing ce|| death in a ce|| where p53 function is compromised , comprising inhibiting. the function of Dicer. The method according to c|aim 1 , wherein the ce|| death is due to synthetic |etha|ity. The method according to c|aim 1 or 2 , wherein the ce|| is further characterized by activation of an. oncogene or inhibition of a tumor suppressor gene. The method according to any one of c|aims 1 to 3 , wherein the ce|| is a tumour ce||. The method according to c|aim 4 , wherein the tumour is a retinob|astoma. The meth0d according t0 c|aim 5 , wherein the function of Dicer1 is inhibited by inhibiting one or. m0re of the miRNAs that are upregu|ated in the ce|| where p53 function is impaired. The method according to c|aim 5 , wherein the miRNA is se|ected from the miR 17 - 92 c|uster , . particu|ar|y se|ected from miR - 17 , miR - 18a , miR - 19a , miR - 19b , miR - 20a and miR - 92. The method according to c|aim 6 or 7 , wherein inhibition of the miRNAs is with an LNA or an. antagomir. The method according to any one of c|aims 1 to 5 , wherein inhibiting the function of Dicer is done. by inhibition of the Dicer1 gene , the Dicer1 mRNA or the Dicer protein. The meth0d according to any 0ne 0f c|aims 1 t0 9 , wherein p53 function is impaired by functi0na|. dysregu|ation but not mutation. The method according t0 any 0ne 0f c|aims 1 t0 9 , wherein p53 function is impaired by at |east 0ne. mutation. An inhibitor of Dicer function for use in treatment of cancer. The inhibitor according to c|aim 12 , wherein the cancer is retinob|astoma. The inhibitor according to c|aim 13 , which is an inhibitor of one or more of the miRNAs that are. upregu|ated in the cancer ce||s. The inhibitor according to c|aim 14 , wherein the miRNA is se|ected from the miR 17 - 92 c|uster , . particu|ar|y se|ected from miR - 17 , miR - 18a , miR - 19a , miR - 19b , miR - 20a and miR - 92. 43. WO 2012l013821 PCT / EP2011 / 063233. 16. The inhibitor according to c|aim 12 or 13 , which is an inhibitor of the Dicer1 gene , the Dicer1 mRNA. or the Dicer protein. 44. WO 2012l013821 PCTlEP2011l063233 1l7. Figure 1. A. . 10° ‘ ...1. QKO ( 0=19 ) . - £ - TKO ( n2l30 ) . 80 l - - ' - - DKO ( ﬂ : 21 ) 60. . % mice free of wsIbly apparent retinoblastoma. . 49 P<0 , 0001 ( * * " ) 20 g 0 i i i . r t u - s 0 100 200 3OO 400 time [ days ] . . SUBST|TUTE SHEET ( RULE 26 ) . WO 2012 / 013821 PCTlEP2011l063233 2l7. . Syntaxin. . . Ca|bindin. . SUBST|TUTE SHEET ( RULE 26 ) . WO 2012 / 013821 3l7. Figure 2. A. Chx 1 OOre ; Rb°"”°" ; p 10 7‘ / ‘ , : Dicer1°X / °X p53 + / “ ' p53iox / lox. { . i . . ‘ . ' . , - "h - K ; ' 5 : . . ‘ ‘ “‘ - ‘fLE ' , ' mmwa ms W : 44% GL‘. . , w , - - . : 4 ; . . s ' ' w. Rb°"”°" ; p 107 : / ' , ' Dicer1°X / °X p53 + / ' + p53ioxﬂox. . . . Chxi 0—Cre~ 1 * Chx10 - Cre + . . ; “m ; - . , € , : ' . : _ ._ é . , , - .§_m , . . , . a ( . SUBST|TUTE SHEET ( RULE 26 ) . PCTlEP2011l063233. PCTlEP2011l063233. WO 2012 / 013821. ¢U7. . . . . . 888 .<aa_ anhmn BB m6 EB o. u #36 mé o. n. m né BB o. n. m 66 n. m 99m n. o BB EEEE xo§2mmn ”xo$2 : mo.~Q 83o‘me ” + \ + : mo.~Q xo§omea ”xowx9hLmomQ $. me ”xo§c~ : mo.~Q a o 8va a m g 5 v i T. . . _ . v oSQ. v_mn. v. . tmoE . xm. Ev tmoE E. 88 . xm. . . £££ Ami. . . 88 E. : 85 E. SUBST|TUTE SHEET ( RULE 26 ) . WO 2012l013821 PC T / EP2011 / 063233. 5l7. Figure 3 A. . ..1 - n - 1 - J ' ." mN , !nm. nnnnai mmm retina nennai mmm raw mudne meter 1 mmm mmm. . . . . . mRr ' y M1106a ‘ m1R - 20a mtR - m mRQ - s miR - 106b - : miR - 92 miRe ' rea - miR - I. - 9o. . . . ( . a : e ) . . . , a‘__ o. , . ' £e5i$i9 ; n._ : - ieve1?S Q‘ E b. a . a 8 do a. veE. tt. , . - { ym . , ..<. . . g . V. ii q o. . . . ‘R¢ ' l3f. noma! “WEﬁfIéRB ' J. Y79. Rst ' na. SUBST|TUTE SHEET ( RULE 26 ) . WO 2012 / 013821 PCT / EP2011 / 063233 6l7. 10O , . - - . , . _._. , , . ._.._. - . . - . . . . - . . M 3. \O Q. . . . . : < xuﬂm! m m . Iwmmm‘mmem : mm‘m. mmi. mwmr . , ma www. miR~1.7 miR~18 miR - 19 miR - 20 miR - 92. Relative Celi Viabiiity ( % ) m 0. Iv——> p53 inactivation - - - ——§ Tumourigenesis. e°g"°§§°.2 ; °ciil°2i!2°n >— * AP°Pt°Se |——— - > Dicer1loss ————I> Survival. ( or miR~17~92 inhibition ) . SUBST|TUTE SHEET ( RULE 26 ) . WO 2012 / 013821 PCTlEP2011l063233 7l7. Figure 4. A. . Chx1O. . . . . P35. _ . ; : "s. n - - - 1"‘. a£. , . Wﬁh‘ : : ; Ur ".4 - { _ - ‘__..~‘ .1 ; - ; ; ; £. m - . Dicer1 + + . . Dicer1 ' °x”°<. . 5&de. ‘ ' MM. , >N.0§.41 ‘. . SUBST|TUTE SHEET ( RULE 26 ) . |NTERNAT|ONAL SEARCH REPORT. . |nternationa| app|ication No. PCT / EP201l / 063233. . . A. CLASS|F|CAT|ON OF SUBJECT MATTER. INV. Cl2Nl5 / 1l3 A6lK3l / 7088 ADD. A61P35 / 00. According to |nternationa| Patent C|assification ( |PC ) or to both nationa| c|assification and |PC. . B. F|ELDS SEARCHED. . Cl2N A61K. Minimum documentation searched ( c|assification system fo||owed by c|assification symbo|s ) . . Documentation searched other than minimum documentation to the extent that such documents are inc|uded in the fie|ds searched. . EPO - InternaI , BIOSIS. E|ectronic data base consu|ted during the internationa| search ( name of data base and , where practica| , search terms used ) . . C. DOCUMENTS CONS|DERED TO BE RELEVANT. . Category * Citation of document , with indication , where appropriate , of the re|evant passages. Re|evant to c|aim No. . X NITTNER D. ET AL. : EJC SUPPLEMENTS , 98 , XP002661054 , & 21ST MEETING 0F THE. ISSN : lB59 - 6349 the whoIe document. . voI. 8 , no. 5 , June 2010 ( 20l0 - 06 ) , page. EUROPEAN - ASSOCIATION - FOR - CANCER - RESEARCH ; 0$L0 , NORWAY ; JUNE 26 - 29 , 20l0. "Dicerl is a synthetic 1 - l6 IethaI partner of tum0ur suppressor p53" , . . . . . . X Further documents are |isted in the continuation of Box C. . . . . X See patent fami|y annex. . . * Specia| categories of cited documents : . "A" document defining the genera| state of the art which is not considered to be of particu|ar re|evance. "E" ear|ier document but pub|ished on or after the internationa| fi|ing date. "L" documentwhich may throw doubts on priority c|aim ( s ) or which is cited to estab|ish the pub|ication date of another citation or other specia| reason ( as specified ) . "O" document referring to an ora| disc|osure , use , exhibition or other means. "P" document pub|ished prior to the internationa| fi|ing date but |aterthan the priority date c|aimed. n. "Y. " |ater document pub|ished after the internationa| fi|ing date. or priority date and not in conf|ict with the app|ication but cited to understand the princip|e or theory under|ying the invention. " document of particu|ar re|evance ; the c|aimed invention. cannot be considered nove| or cannot be considered to invo|ve an inventive step when the document is taken a|one. " document of particu|ar re|evance ; the c|aimed invention. cannot be considered to invo|ve an inventive step when the document is combined with one or more other such documents , such combination being obvious to a person ski||ed in the art. " document member of the same patent fami|y. . Date of the actua| comp|etion of the internationa| search. 12 0ctober 201l. Date of mai|ing of the internationa| search report. 07 / ll / 20ll. . Name and mai|ing address of the |SAl. European Patent Office , PB 5818 Patent|aan 2 NL - 2280 HV Rijswijk. Te|. ( + 31 - 70 ) 340 - 2040 , . Fax : ( + 31 - 70 ) 340 - 3016. . . Authorized officer. Macchia , Giovanni. . F0rm PCTl|SAl21O ( sec0nd sheet ) ( Apri| 2005 ) . page 1 0f 2. . . |NTERNAT|ONAL SEARCH REPORT. |nternationa| app|ication No. PCT / EP2011 / 063233. . . C ( C0ntinuati0n ) . DOCUMENTS CONS|DERED TO BE RELEVANT. . Category * Oitation of document , with indication , where appropriate , of the re|evant passages Re|evant to c|aim No. . A LAMBERTZ I. ET AL. : "MonoaIIeIic but not 1 - 16 biaIIeIic Ioss of Dicer1 promotes tumorigenesis in vivo" , . CELL DEATH AND DIFFERENTIATION , . voI. 17 , no. 4 , 1 ApriI 2010 ( 2010 - 04 - 01 ) , pages 633 - 641 , XP055008885 , . ISSN : 1350 - 9047 , D01 : 10.1038 / cdd.2009.202 cited in the appIication. the whoIe document. A YAN LI ET AL : "Targeted deIetion 0f Dicer 1 - 16 disrupts Iens morphogenesis , corneaI epitheIium stratification , and whoIe eye deveIopment" , . DEVELOPMENTAL DYNAMICS , . voI. 238 , no. 9 , . 1 September 2009 ( 2009 - 09 - 01 ) , pages 2388 - 2400 , XP055008881 , . ISSN : 1058 - 8388 , 001 : 10.1002 / dvdy.22056 the whoIe document. - & YAN LI ET AL : "Supporting Information : Targeted deIetion of Dicer disrupts Iens morphogenesis , corneaI epitheIium stratification , and whoIe eye deveIopment" , . DEVELOPMENTAL DYNAMICS. voI. 238 , no. 9. September 2009 ( 2009 - 09 ) , XP002661055 , Retrieved from the Internet : URL : http : / / onIineIibrary. wiIey. com / doi / 10. 1002 / dvdy.22056 / suppinfo. [ retrieved on 2011 - 10 - 06 ] . the whoIe document. A w0 2009 / 102225 A2 ( INSTYTUT CHEMII 1 - 16 BIO0RGANICZNEJ PAN [ PL ] ) . 20 August 2009 ( 2009 - 08 - 20 ) the whoIe document. . . . . . F0rm PCTl|SAl21O ( continuati0n of second sheet ) ( Apri| 2005 ) . page 2 0f 2. . |NTERNAT|ONAL SEARCH REPORT. |nternationa| app|ication No |nformation on patent fami|y members. . . . . . . PCT / EP2011 / 063233 Patent d oooooo t Pub|ication Patent fami|y Pub|ication cited in search report date member ( s ) date M0 2009l02225 A2 20 - 08 - 2009 EP 2255002 A2 01 - l2 - 20l0 US 20ll207l97 Al 25 - 08 - 20ll. . . . F0rm PCTl|SAl21O ( patent fami|y annex ) ( Apri| 2005 )